No. |
薬物名(臨床試験情報から抽出) |
DrugBank |
KEGG DRUG * |
KEGG GENES * |
KEGG PATHWAY |
指定難病告示番号 * |
1 |
(-)-trans-delta-9-tetrahydrocannabinol |
Dronabinol |
D00306 |
2件: CNR1, CNR2 |
4件: Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis |
1件: 13 |
2 |
(im) avonex® |
Interferon beta-1a |
D04554 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
3 |
(r) 3-(5-dimethylcarbamoyl-pent-1-enyl)-n-(2-hydroxy-1- methylethyl) benzamide |
Pentaerythritol tetranitrate |
D01721 |
- |
- |
1件: 13 |
4 |
0,5 mg fingolimod |
Fingolimod |
D10001 |
1件: S1PR1 |
3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway |
1件: 13 |
5 |
0.25mg rpc1063 |
- |
- |
- |
- |
1件: 13 |
6 |
1 - andrographis paniculata p/st extract |
- |
- |
- |
- |
1件: 13 |
7 |
1% steroid cream |
- |
- |
- |
- |
1件: 13 |
8 |
1-{6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1h-3-benzazepin-7-yl)oxy]-3-pyridinyl}-2-pyrrolidinone |
- |
- |
- |
- |
1件: 13 |
9 |
1.0mg rpc1063 |
- |
- |
- |
- |
1件: 13 |
10 |
10 milligram (mg) fampridine-sr (4-aminopyridine, 4-ap) |
Dalfampridine |
D04127 |
2件: KCNA4, KCND2 |
3件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse |
1件: 13 |
11 |
10000iu vitamin d |
Vitamin d |
- |
- |
- |
1件: 13 |
12 |
11c-acetate |
Acetate |
- |
- |
- |
3件: 13, 86, 88 |
13 |
11c-pib |
- |
- |
- |
- |
1件: 13 |
14 |
13-pcv booster |
- |
- |
- |
- |
1件: 13 |
15 |
13-valent pneumococcal conjugate vaccine (13-pcv) |
- |
- |
- |
- |
1件: 13 |
16 |
15 mg fampridine-sr (4-aminopyridine, 4-ap) |
Dalfampridine |
D04127 |
2件: KCNA4, KCND2 |
3件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse |
1件: 13 |
17 |
18f-dpa-714 and 18f-fdg |
Fludeoxyglucose f-18 |
- |
- |
- |
1件: 13 |
18 |
18f-fdg |
Fludeoxyglucose f-18 |
- |
- |
- |
7件: 6, 13, 46, 53, 84, 127, 300 |
19 |
19 nor vitamin d |
Vitamin d |
- |
- |
- |
1件: 13 |
20 |
2 - excipients |
- |
- |
- |
- |
1件: 13 |
21 |
2-cda |
Cladribine |
D01370 |
1件: RRM1 |
5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
1件: 13 |
22 |
2-cda, 2-chloro-2’-deoxy-beta-d-adenosine |
Adenosine |
D00045 |
4件: ADORA1, ADORA2A, ADORA2B, ADORA3 |
12件: Alcoholism, Calcium signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 13 |
23 |
2-cda, 2-chloro-2’-deoxy-ß-d-adenosine |
Adenosine |
D00045 |
4件: ADORA1, ADORA2A, ADORA2B, ADORA3 |
12件: Alcoholism, Calcium signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 13 |
24 |
2-chloro-2'-deoxyadenosine, 2cda |
Cladribine |
D01370 |
1件: RRM1 |
5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
1件: 13 |
25 |
2-chloro-2’-deoxyadenosine (2-cda) |
Cladribine |
D01370 |
1件: RRM1 |
5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
1件: 13 |
26 |
20 mg fampridine-sr (4-aminopyridine, 4-ap) |
Dalfampridine |
D04127 |
2件: KCNA4, KCND2 |
3件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse |
1件: 13 |
27 |
20 mg ga |
- |
- |
- |
- |
1件: 13 |
28 |
200106 or emd 28162 |
- |
- |
- |
- |
1件: 13 |
29 |
20mg/0.5ml ga |
- |
- |
- |
- |
1件: 13 |
30 |
20mg/0.5ml glatiramer acetate |
Glatiramer |
D04318 |
20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G |
32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease (IBD), Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
1件: 13 |
31 |
23-ppv |
- |
- |
- |
- |
1件: 13 |
32 |
23-valent pneumococcal polysaccharide vaccine |
- |
- |
- |
- |
3件: 13, 46, 53 |
33 |
23-valent pneumococcal polysaccharide vaccine (23-ppv) |
- |
- |
- |
- |
1件: 13 |
34 |
25oh-vitamin d |
Vitamin d |
- |
- |
- |
1件: 13 |
35 |
2b3-201 |
- |
- |
- |
- |
1件: 13 |
36 |
2cda |
Cladribine |
D01370 |
1件: RRM1 |
5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
1件: 13 |
37 |
3 mg melatonin |
Melatonin |
D08170 |
2件: MTNR1A, MTNR1B |
2件: Circadian entrainment, Neuroactive ligand-receptor interaction |
1件: 13 |
38 |
3,4-diaminopyridine |
- |
- |
- |
- |
3件: 11, 12, 13 |
39 |
4-aminopyridine |
Dalfampridine |
D04127 |
2件: KCNA4, KCND2 |
3件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse |
2件: 3, 13 |
40 |
4-ap |
Dalfampridine |
D04127 |
2件: KCNA4, KCND2 |
3件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse |
1件: 13 |
41 |
4.5 mg naltrexone |
Naltrexone |
D02095, D05113 |
3件: OPRD1, OPRK1, OPRM1 |
5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
1件: 13 |
42 |
40 mg ga |
- |
- |
- |
- |
2件: 2, 13 |
43 |
40 mg glatiramer acetate |
Glatiramer |
D04318 |
20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G |
32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease (IBD), Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
2件: 2, 13 |
44 |
5 mg melatonin |
Melatonin |
D08170 |
2件: MTNR1A, MTNR1B |
2件: Circadian entrainment, Neuroactive ligand-receptor interaction |
1件: 13 |
45 |
5000iu vitamin d |
Vitamin d |
- |
- |
- |
1件: 13 |
46 |
52069.00.01 |
- |
- |
- |
- |
1件: 13 |
47 |
9060x |
- |
- |
- |
- |
2件: 13, 149 |
48 |
95% pure ecgc capsules 200mg |
- |
- |
- |
- |
1件: 13 |
49 |
[11c]flumazenil |
Flumazenil |
D00697 |
16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
1件: 13 |
50 |
[123i]clinde |
- |
- |
- |
- |
2件: 6, 13 |
51 |
[14c]-rpc1063 solution (0.1 mg/ml) for oral administration |
- |
- |
- |
- |
3件: 13, 96, 97 |
52 |
[18f] pbr06 |
- |
- |
- |
- |
2件: 6, 13 |
53 |
[18f]-feppa |
- |
- |
- |
- |
2件: 6, 13 |
54 |
[18f]dpa-714 |
- |
- |
- |
- |
1件: 13 |
55 |
[18f]florbetapir and pet imaging |
- |
- |
- |
- |
1件: 13 |
56 |
[c-11]methylreboxetine |
- |
- |
- |
- |
1件: 13 |
57 |
[f-18]pbr06 |
- |
- |
- |
- |
1件: 13 |
58 |
[zr-89]oxine-labeled leukocytes pet/mr |
Oxyquinoline |
D05321 |
- |
- |
1件: 13 |
59 |
A4i antagonist |
- |
- |
- |
- |
1件: 13 |
60 |
Ab1010 |
Masitinib |
D10229 |
1件: KIT |
11件: Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer, Hematopoietic cell lineage, MAPK signaling pathway, Melanogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway |
6件: 2, 5, 6, 13, 46, 96 |
61 |
Abatacept |
Abatacept |
D03203 |
2件: CD80, CD86 |
12件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis |
24件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 96, 97, 107, 164, 222, 271, 284, 285, 300 |
62 |
Abobotulinumtoxin a |
- |
- |
- |
- |
1件: 13 |
63 |
Abr-215062 sodium salt |
- |
- |
- |
- |
2件: 13, 96 |
64 |
Abt-555 |
- |
- |
- |
- |
1件: 13 |
65 |
Abt-874/human monoclonal antibody against il-12 |
- |
- |
- |
- |
1件: 13 |
66 |
Abx-1431 hcl |
- |
- |
- |
- |
1件: 13 |
67 |
Acetaminophen |
Acetaminophen |
D00217 |
2件: PTGS1, PTGS2 |
21件: Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
11件: 13, 34, 35, 46, 49, 51, 70, 86, 231, 256, 271 |
68 |
Acetaminophen tab 650mg |
Acetaminophen |
D00217 |
2件: PTGS1, PTGS2 |
21件: Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
1件: 13 |
69 |
Acetate |
Acetate |
- |
- |
- |
40件: 1, 2, 6, 10, 13, 35, 40, 46, 49, 51, 60, 64, 70, 71, 73, 75, 76, 78, 81, 83, 85, 86, 88, 90, 96, 97, 113, 145, 156, 162, 171, 206, 222, 224, 225, 235, 265, 288, 298, 299 |
70 |
Acetazolamide |
Acetazolamide |
D00218, D01196 |
13件: CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA8, CA9 |
7件: Bile secretion, Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Nitrogen metabolism, Pancreatic secretion, Proximal tubule bicarbonate reclamation |
6件: 13, 90, 115, 155, 225, 230 |
71 |
Acetylcysteine |
Acetylcysteine |
D00221 |
- |
- |
14件: 6, 13, 19, 20, 49, 51, 58, 85, 94, 111, 164, 233, 298, 299 |
72 |
Acetylsalicylic acid |
Acetylsalicylic acid |
D00109 |
2件: PTGS1, PTGS2 |
21件: Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
3件: 13, 46, 51 |
73 |
Acetylsalicylic acid at 1st visit, |
Acetylsalicylic acid |
D00109 |
2件: PTGS1, PTGS2 |
21件: Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
1件: 13 |
74 |
Aclasta |
Zoledronic acid |
D01968, D06378, D06379, D08689 |
1件: FDPS |
4件: Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis |
3件: 13, 271, 274 |
75 |
Aclasta 5 mg infusionslösung |
Zoledronic acid |
D01968, D06378, D06379, D08689 |
1件: FDPS |
4件: Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis |
1件: 13 |
76 |
Aclasta 5mg solution for infusion |
Zoledronic acid |
D01968, D06378, D06379, D08689 |
1件: FDPS |
4件: Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis |
1件: 13 |
77 |
Act-128800 |
Ponesimod |
D11215 |
1件: S1PR1 |
3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway |
1件: 13 |
78 |
Act-128800 dose 1 |
Ponesimod |
D11215 |
1件: S1PR1 |
3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway |
1件: 13 |
79 |
Act-128800 dose 2 |
Ponesimod |
D11215 |
1件: S1PR1 |
3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway |
1件: 13 |
80 |
Act-128800 dose 3 |
Ponesimod |
D11215 |
1件: S1PR1 |
3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway |
1件: 13 |
81 |
Acth |
Corticotropin |
D00146 |
1件: MC2R |
5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
5件: 13, 66, 145, 193, 222 |
82 |
Acthar |
Corticotropin |
D00146 |
1件: MC2R |
5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
6件: 2, 13, 46, 49, 50, 222 |
83 |
Acthar gel |
- |
- |
- |
- |
4件: 13, 46, 49, 84 |
84 |
Acthar gel (acth) |
Corticotropin |
D00146 |
1件: MC2R |
5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
1件: 13 |
85 |
Active comparator receiving extavia® |
- |
- |
- |
- |
1件: 13 |
86 |
Active control |
- |
- |
- |
- |
1件: 13 |
87 |
Actos (pioglitazone) |
Pioglitazone |
D00945, D08378 |
1件: PPARG |
9件: AMPK signaling pathway, Huntington disease, Longevity regulating pathway, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer |
1件: 13 |
88 |
Acyclovir |
Acyclovir |
D00222 |
- |
- |
2件: 13, 28 |
89 |
Adderall xr |
- |
- |
- |
- |
1件: 13 |
90 |
Adderall xr 10 mg |
- |
- |
- |
- |
1件: 13 |
91 |
Adderall xr 5mg |
- |
- |
- |
- |
1件: 13 |
92 |
Adenosine |
Adenosine |
D00045 |
4件: ADORA1, ADORA2A, ADORA2B, ADORA3 |
12件: Alcoholism, Calcium signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
3件: 13, 58, 65 |
93 |
Adrenocorticotropic hormone |
Corticotropin |
D00146 |
1件: MC2R |
5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
3件: 13, 50, 84 |
94 |
Adrenocorticotropic hormone (acth) gel (h.p. acthar®) |
Corticotropin |
D00146 |
1件: MC2R |
5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
1件: 13 |
95 |
Ads-5102 |
- |
- |
- |
- |
2件: 6, 13 |
96 |
Ads-5102, 137 mg |
- |
- |
- |
- |
1件: 13 |
97 |
Ads-5102, 274 mg |
- |
- |
- |
- |
1件: 13 |
98 |
Aert, (r)-baclofen |
Baclofen |
D00241 |
2件: GABBR1, GABBR2 |
7件: Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway |
1件: 13 |
99 |
Agee cream |
- |
- |
- |
- |
1件: 13 |
100 |
Aimspro |
- |
- |
- |
- |
2件: 13, 51 |
101 |
Ain457 |
- |
- |
- |
- |
7件: 13, 37, 41, 46, 56, 96, 271 |
102 |
Alanine |
L-alanine |
D00012 |
- |
- |
3件: 13, 298, 299 |
103 |
Albumin (human) 25%, united states pharmacopeia (usp) |
- |
- |
- |
- |
2件: 13, 14 |
104 |
Albuterol |
Salbutamol |
D02147 |
1件: ADRB2 |
8件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
8件: 12, 13, 86, 89, 113, 231, 256, 299 |
105 |
Alcohol |
Ethanol |
D00068, D02798, D04855, D06542 |
- |
- |
4件: 13, 58, 279, 298 |
106 |
Alemtuzumab |
Alemtuzumab |
D02802 |
- |
- |
13件: 13, 15, 19, 20, 46, 51, 60, 63, 65, 85, 96, 164, 284 |
107 |
Alemtuzumab (gz402673) |
Alemtuzumab |
D02802 |
- |
- |
1件: 13 |
108 |
Alemtuzumab 12 mg |
Alemtuzumab |
D02802 |
- |
- |
1件: 13 |
109 |
Alemtuzumab 24 mg |
Alemtuzumab |
D02802 |
- |
- |
1件: 13 |
110 |
Alemtuzumab gz402673 |
Alemtuzumab |
D02802 |
- |
- |
1件: 13 |
111 |
Alemtuzumab immunotherapy |
Alemtuzumab |
D02802 |
- |
- |
1件: 13 |
112 |
Alemtuzumab injection [lemtrada] |
Alemtuzumab |
D02802 |
- |
- |
1件: 13 |
113 |
Alfuzosin |
Alfuzosin |
D01692, D07124 |
1件: ADRA1A |
7件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
1件: 13 |
114 |
Alks 8700 |
- |
- |
- |
- |
1件: 13 |
115 |
Alks 8700 delayed release (dr) |
- |
- |
- |
- |
1件: 13 |
116 |
Alks 8700 delayed release (dr) capsule |
- |
- |
- |
- |
1件: 13 |
117 |
Allogeneic human umbilical cord tissue-derived mesenchymal stem cells |
- |
- |
- |
- |
1件: 13 |
118 |
Alpha lipoic acid |
Lipoic acid |
D00048, D00086 |
- |
- |
1件: 13 |
119 |
Alpha-lipoic acid |
Lipoic acid |
D00048, D00086 |
- |
- |
2件: 2, 13 |
120 |
Alpha1-antitrypsin |
- |
- |
- |
- |
1件: 13 |
121 |
Altri farmaci del sistema nervoso |
- |
- |
- |
- |
1件: 13 |
122 |
Amantadine |
Amantadine |
D00777, D07441 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
4件: 6, 8, 13, 127 |
123 |
American ginseng |
Ginseng |
D06772 |
- |
- |
1件: 13 |
124 |
American ginseng extract ht-1001 |
Ginseng |
D06772 |
- |
- |
1件: 13 |
125 |
Amiloride |
Amiloride |
D00649, D07447 |
3件: SCNN1A, SCNN1B, SCNN1G |
2件: Aldosterone-regulated sodium reabsorption, Taste transduction |
3件: 13, 225, 299 |
126 |
Amiloride hydrochloride |
Amiloride |
D00649, D07447 |
3件: SCNN1A, SCNN1B, SCNN1G |
2件: Aldosterone-regulated sodium reabsorption, Taste transduction |
1件: 13 |
127 |
Amiloride hydrochloride, 2 h2o |
Amiloride |
D00649, D07447 |
3件: SCNN1A, SCNN1B, SCNN1G |
2件: Aldosterone-regulated sodium reabsorption, Taste transduction |
1件: 13 |
128 |
Amilostad hct |
- |
- |
- |
- |
1件: 13 |
129 |
Amilostad hct tablets |
- |
- |
- |
- |
1件: 13 |
130 |
Ampyra |
Dalfampridine |
D04127 |
2件: KCNA4, KCND2 |
3件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse |
1件: 13 |
131 |
An100226 |
- |
- |
- |
- |
2件: 13, 96 |
132 |
An100226, bg00002 |
- |
- |
- |
- |
1件: 13 |
133 |
Anakinra |
Anakinra |
D02934 |
2件: IL1R1, IL1R2 |
15件: Amoebiasis, Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, MAPK signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Pathogenic Escherichia coli infection, Prostate cancer, Shigellosis, Th17 cell differentiation, Transcriptional misregulation in cancer |
15件: 2, 13, 15, 19, 37, 41, 46, 49, 50, 56, 84, 86, 106, 107, 299 |
134 |
Androgel 1 % topical gel |
- |
- |
- |
- |
1件: 13 |
135 |
Androgel 100mg gel |
- |
- |
- |
- |
1件: 13 |
136 |
Andrographolides |
- |
- |
- |
- |
1件: 13 |
137 |
Anesthetic topical adhesive synera |
- |
- |
- |
- |
1件: 13 |
138 |
Anti lp40 antibody, subclass igg4 la294 |
- |
- |
- |
- |
2件: 13, 46 |
139 |
Anti-cd25 humanized monoclonal antibody |
- |
- |
- |
- |
1件: 13 |
140 |
Anti-cd52 monoclonal antibody |
- |
- |
- |
- |
1件: 13 |
141 |
Anti-il-12 |
- |
- |
- |
- |
2件: 13, 96 |
142 |
Anti-thymocyte globulin |
- |
- |
- |
- |
18件: 11, 13, 14, 36, 40, 41, 42, 45, 46, 49, 51, 60, 62, 65, 164, 283, 284, 285 |
143 |
Anticholinergic medication |
- |
- |
- |
- |
1件: 13 |
144 |
Antihistamine |
- |
- |
- |
- |
2件: 13, 46 |
145 |
Antimycotic |
- |
- |
- |
- |
1件: 13 |
146 |
Antithymocyte |
- |
- |
- |
- |
1件: 13 |
147 |
Antithymocyte immunoglobulin (rabbit) |
Rabbit |
- |
- |
- |
2件: 13, 65 |
148 |
Arbaclofen |
Arbaclofen |
D09791 |
2件: GABBR1, GABBR2 |
7件: Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway |
2件: 13, 206 |
149 |
Arbaclofen er tablets |
Arbaclofen |
D09791 |
2件: GABBR1, GABBR2 |
7件: Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway |
1件: 13 |
150 |
Arbaclofen extended release tablets |
Arbaclofen |
D09791 |
2件: GABBR1, GABBR2 |
7件: Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway |
1件: 13 |
151 |
Arbaclofen placarbil |
Arbaclofen placarbil |
D08861 |
2件: GABBR1, GABBR2 |
7件: Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway |
1件: 13 |
152 |
Arbaclofen placarbil 15 mg bid |
Arbaclofen placarbil |
D08861 |
2件: GABBR1, GABBR2 |
7件: Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway |
1件: 13 |
153 |
Arbaclofen placarbil 30 mg bid |
Arbaclofen placarbil |
D08861 |
2件: GABBR1, GABBR2 |
7件: Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway |
1件: 13 |
154 |
Arbaclofen placarbil 45 mg bid |
Arbaclofen placarbil |
D08861 |
2件: GABBR1, GABBR2 |
7件: Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway |
1件: 13 |
155 |
Aricept |
Donepezil |
D00670, D07869 |
1件: ACHE |
2件: Cholinergic synapse, Glycerophospholipid metabolism |
4件: 6, 13, 78, 124 |
156 |
Aricept 10 mg |
Donepezil |
D00670, D07869 |
1件: ACHE |
2件: Cholinergic synapse, Glycerophospholipid metabolism |
1件: 13 |
157 |
Aricept 10 mg filmdragerade tabletter |
Donepezil |
D00670, D07869 |
1件: ACHE |
2件: Cholinergic synapse, Glycerophospholipid metabolism |
1件: 13 |
158 |
Aricept 5 mg |
Donepezil |
D00670, D07869 |
1件: ACHE |
2件: Cholinergic synapse, Glycerophospholipid metabolism |
1件: 13 |
159 |
Aricept 5 mg filmdragerade tabletter |
Donepezil |
D00670, D07869 |
1件: ACHE |
2件: Cholinergic synapse, Glycerophospholipid metabolism |
1件: 13 |
160 |
Arm 1 - geh120714 (18f) injection |
- |
- |
- |
- |
1件: 13 |
161 |
Armodafinil |
Armodafinil |
D03215 |
1件: SLC6A3 |
6件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Synaptic vesicle cycle |
3件: 6, 13, 84 |
162 |
Arn-6039 |
- |
- |
- |
- |
1件: 13 |
163 |
Arzerra |
Ofatumumab |
D09314 |
1件: MS4A1 |
1件: Hematopoietic cell lineage |
1件: 13 |
164 |
Asb-683699 |
- |
- |
- |
- |
1件: 13 |
165 |
Aspartate |
Aspartic acid |
D00013 |
- |
- |
3件: 13, 75, 299 |
166 |
Aspirin |
Acetylsalicylic acid |
D00109 |
2件: PTGS1, PTGS2 |
21件: Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
10件: 13, 22, 34, 46, 49, 51, 86, 113, 158, 231 |
167 |
Aspirin 650mg oral capsule |
Acetylsalicylic acid |
D00109 |
2件: PTGS1, PTGS2 |
21件: Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
1件: 13 |
168 |
Ata188 |
- |
- |
- |
- |
1件: 13 |
169 |
Atacicept |
Atacicept |
D09704 |
2件: TNFSF13, TNFSF13B |
4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis |
4件: 13, 46, 49, 66 |
170 |
Atacicept 150 mg |
Atacicept |
D09704 |
2件: TNFSF13, TNFSF13B |
4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis |
3件: 13, 49, 66 |
171 |
Atacicept 25 mg |
Atacicept |
D09704 |
2件: TNFSF13, TNFSF13B |
4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis |
2件: 13, 66 |
172 |
Atacicept 75 mg |
Atacicept |
D09704 |
2件: TNFSF13, TNFSF13B |
4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis |
3件: 13, 49, 66 |
173 |
Atl1102 |
Atl1102 |
- |
- |
- |
1件: 13 |
174 |
Atomoxetine |
Atomoxetine |
D02574, D07473 |
1件: SLC6A2 |
1件: Synaptic vesicle cycle |
3件: 6, 8, 13 |
175 |
Atorvastatin |
Atorvastatin |
D00258, D00887, D07474 |
1件: HMGCR |
4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
17件: 13, 46, 49, 51, 58, 63, 79, 84, 88, 93, 96, 160, 222, 225, 265, 271, 299 |
176 |
Atx-ms-1467 |
- |
- |
- |
- |
1件: 13 |
177 |
Aubagio |
Teriflunomide |
D10172 |
1件: DHODH |
2件: Metabolic pathways, Pyrimidine metabolism |
1件: 13 |
178 |
Aubagio - 14 mg - compressa rivestita con film - uso orale - blister (alu/alu) - 28 compresse |
Teriflunomide |
D10172 |
1件: DHODH |
2件: Metabolic pathways, Pyrimidine metabolism |
1件: 13 |
179 |
Aubagio® |
- |
- |
- |
- |
1件: 13 |
180 |
Autologous adipose derived mesenchymal cells |
- |
- |
- |
- |
1件: 13 |
181 |
Autologous adult mesenchymal stem cells from bone marrow expanded and cryopreserved |
- |
- |
- |
- |
1件: 13 |
182 |
Autologous bone marrow-derived mononuclear stem cells |
- |
- |
- |
- |
1件: 13 |
183 |
Autologous cd4+t cells stimulated and expanded ex vivo by a mog peptide modified by the introduction of a thioreductase motif into the flanking residues of the t cell epitope |
- |
- |
- |
- |
1件: 13 |
184 |
Autologous hematopoietic stem cell |
- |
- |
- |
- |
1件: 13 |
185 |
Autologous mesenchymal cell product |
- |
- |
- |
- |
1件: 13 |
186 |
Autologous mesenchymal stem cell transplantation |
- |
- |
- |
- |
1件: 13 |
187 |
Autologous mesenchymal stem cells |
- |
- |
- |
- |
5件: 2, 6, 13, 17, 46 |
188 |
Autologous stem cells |
- |
- |
- |
- |
2件: 13, 51 |
189 |
Autologous t-lymphocytes |
- |
- |
- |
- |
1件: 13 |
190 |
Autologous vitd3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (toldc-vitd3) |
- |
- |
- |
- |
1件: 13 |
191 |
Av605 |
- |
- |
- |
- |
1件: 13 |
192 |
Avonex |
Interferon beta-1a |
D04554 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
2件: 13, 97 |
193 |
Avonex (interferon beta 1a) |
Interferon beta-1a |
D04554 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
194 |
Avonex (interferon beta-1a), biogen idec ltd |
Human interferon beta |
- |
- |
- |
1件: 13 |
195 |
Avonex 30 µg/0,5 ml solution for injection |
Interferon beta-1a |
D04554 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
196 |
Avonex and topamax |
- |
- |
- |
- |
1件: 13 |
197 |
Avonex im 4sir 30mcg/0,5ml 4ag |
Interferon beta-1a |
D04554 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
198 |
Avonex/betaseron/copaxone/rebif |
- |
- |
- |
- |
1件: 13 |
199 |
Avonex/zocor |
- |
- |
- |
- |
1件: 13 |
200 |
Avonex® |
- |
- |
- |
- |
1件: 13 |
201 |
Avonex® monotherapy (6.0 miu administered i.m. each week) |
- |
- |
- |
- |
1件: 13 |
202 |
Avp-923 |
- |
- |
- |
- |
3件: 2, 6, 13 |
203 |
Azathioprine |
Azathioprine |
D00238, D03033 |
- |
- |
18件: 11, 13, 19, 35, 42, 43, 44, 45, 46, 49, 65, 66, 85, 94, 95, 96, 97, 162 |
204 |
Azatioprina |
Azathioprine |
D00238, D03033 |
- |
- |
3件: 13, 96, 97 |
205 |
Azatioprina hex. 50cpr 50mg bl |
Azathioprine |
D00238, D03033 |
- |
- |
1件: 13 |
206 |
Azithromycin |
Azithromycin |
D02134, D06390, D07486 |
- |
- |
6件: 13, 84, 85, 96, 228, 299 |
207 |
Bacille calmette-guerin vaccine |
- |
- |
- |
- |
1件: 13 |
208 |
Bacille of calmette-guerin |
- |
- |
- |
- |
1件: 13 |
209 |
Baclofen |
Baclofen |
D00241 |
2件: GABBR1, GABBR2 |
7件: Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway |
5件: 2, 10, 13, 18, 149 |
210 |
Baclofen 20 mg |
Baclofen |
D00241 |
2件: GABBR1, GABBR2 |
7件: Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway |
1件: 13 |
211 |
Baclofen ir |
Baclofen |
D00241 |
2件: GABBR1, GABBR2 |
7件: Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway |
1件: 13 |
212 |
Baf312 |
- |
- |
- |
- |
2件: 13, 50 |
213 |
Baf312 0,25 mg tablet |
- |
- |
- |
- |
1件: 13 |
214 |
Baf312 1 mg tablet |
- |
- |
- |
- |
2件: 13, 50 |
215 |
Baf312 4 mg tablet |
- |
- |
- |
- |
1件: 13 |
216 |
Baf312 hemifumarate |
- |
- |
- |
- |
2件: 13, 50 |
217 |
Baf312a |
- |
- |
- |
- |
1件: 13 |
218 |
Bafiertam |
- |
- |
- |
- |
1件: 13 |
219 |
Balance |
Isoxaflutole |
- |
- |
- |
8件: 5, 6, 13, 18, 81, 113, 149, 299 |
220 |
Baminercept |
Baminercept |
D08866 |
1件: LTB |
3件: Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Rheumatoid arthritis |
4件: 13, 46, 53, 97 |
221 |
Baseline treatment |
- |
- |
- |
- |
1件: 13 |
222 |
Bat4406f |
- |
- |
- |
- |
1件: 13 |
223 |
Bay 79-4998 |
- |
- |
- |
- |
1件: 13 |
224 |
Bay86-5046 |
- |
- |
- |
- |
1件: 13 |
225 |
Bay86-5046_interferon-beta-1b |
- |
- |
- |
- |
1件: 13 |
226 |
Bazedoxifene |
Bazedoxifene |
D03062 |
- |
- |
1件: 13 |
227 |
Bazedoxifene acetate |
Bazedoxifene |
D03062 |
- |
- |
1件: 13 |
228 |
Bbr 2778 |
- |
- |
- |
- |
2件: 11, 13 |
229 |
Bcd-033 (interferon beta 1a) |
Interferon beta-1a |
D04554 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
230 |
Bcd-054 180 mcg |
- |
- |
- |
- |
1件: 13 |
231 |
Bcd-054 240 mcg |
- |
- |
- |
- |
1件: 13 |
232 |
Bcd-063 |
- |
- |
- |
- |
1件: 13 |
233 |
Bcd-132 |
- |
- |
- |
- |
1件: 13 |
234 |
Bcg20-0134 |
- |
- |
- |
- |
1件: 13 |
235 |
Beam |
Tricyclazole |
- |
- |
- |
1件: 13 |
236 |
Beam regimen |
Tricyclazole |
- |
- |
- |
1件: 13 |
237 |
Beetainterferoni -1a |
- |
- |
- |
- |
1件: 13 |
238 |
Best available therapy (bat) |
- |
- |
- |
- |
1件: 13 |
239 |
Beta interferon |
Human interferon beta |
- |
- |
- |
1件: 13 |
240 |
Beta-1b interferoni |
- |
- |
- |
- |
1件: 13 |
241 |
Beta-alanine |
L-alanine |
D00012 |
- |
- |
1件: 13 |
242 |
Beta-alanine supplementation |
L-alanine |
D00012 |
- |
- |
1件: 13 |
243 |
Beta-carotene |
Beta carotene |
D03101 |
- |
- |
1件: 13 |
244 |
Beta-interferon |
Human interferon beta |
- |
- |
- |
1件: 13 |
245 |
Betacarotene |
Beta carotene |
D03101 |
- |
- |
1件: 13 |
246 |
Betaferon |
Interferon beta-1b |
D00746 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
247 |
Betaferon 250 microgram/ml |
Interferon beta-1b |
D00746 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
248 |
Betaferon 250 microgram/ml, powder and solvent for solution for injection |
Interferon beta-1b |
D00746 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
249 |
Betaferon 250µg |
Interferon beta-1b |
D00746 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
250 |
Betaferon 500mcg |
Interferon beta-1b |
D00746 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
251 |
Betaferon 500µg |
Interferon beta-1b |
D00746 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
252 |
Betaferon sc 15f 0,25mg 15sir |
Interferon beta-1b |
D00746 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
253 |
Betaferon*15confez 0,25mg/ml+ |
Interferon beta-1b |
D00746 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
254 |
Betaferon, bay 86-5046 |
- |
- |
- |
- |
1件: 13 |
255 |
Betaferon/betaseron |
- |
- |
- |
- |
1件: 13 |
256 |
Betaferon® |
- |
- |
- |
- |
1件: 13 |
257 |
Betaferon® (interferon beta-1b) |
Human interferon beta |
- |
- |
- |
1件: 13 |
258 |
Betaseron |
Interferon beta-1b |
D00746 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
259 |
Betaseron (interferon beta-1b, bay86-5046) |
Human interferon beta |
- |
- |
- |
1件: 13 |
260 |
Betaseron (interferon beta-1b, bay86-5046), bayer healthcare ag |
Human interferon beta |
- |
- |
- |
1件: 13 |
261 |
Betmiga |
Mirabegron |
D09535 |
1件: ADRB3 |
7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, cGMP-PKG signaling pathway |
1件: 13 |
262 |
Bevacizumab |
Bevacizumab |
D06409 |
1件: VEGFA |
21件: AGE-RAGE signaling pathway in diabetic complications, Bladder cancer, EGFR tyrosine kinase inhibitor resistance, Fluid shear stress and atherosclerosis, Focal adhesion, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, MAPK signaling pathway, MicroRNAs in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Relaxin signaling pathway, Renal cell carcinoma, Rheumatoid arthritis, VEGF signaling pathway |
9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 |
263 |
Bexarotene |
Bexarotene |
D03106 |
3件: RXRA, RXRB, RXRG |
15件: Adipocytokine signaling pathway, Bile secretion, Gastric cancer, Hepatitis C, Non-alcoholic fatty liver disease (NAFLD), Non-small cell lung cancer, PI3K-Akt signaling pathway, PPAR signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Thyroid cancer, Thyroid hormone signaling pathway, Transcriptional misregulation in cancer |
2件: 13, 75 |
264 |
Bg00002 |
- |
- |
- |
- |
1件: 13 |
265 |
Bg00002 (natalizumab) |
Natalizumab |
D06886 |
1件: ITGA4 |
14件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection |
1件: 13 |
266 |
Bg00002-e (natalizumab high titer) |
Natalizumab |
D06886 |
1件: ITGA4 |
14件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection |
1件: 13 |
267 |
Bg00012 |
Dimethyl fumarate |
D03846 |
1件: KEAP1 |
4件: Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Pathways in cancer, Ubiquitin mediated proteolysis |
2件: 13, 46 |
268 |
Bg00012 (dmf) |
Dimethyl fumarate |
D03846 |
1件: KEAP1 |
4件: Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Pathways in cancer, Ubiquitin mediated proteolysis |
1件: 13 |
269 |
Bg00012 (dmf) (tecfidera®.) |
Dimethyl fumarate |
D03846 |
1件: KEAP1 |
4件: Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Pathways in cancer, Ubiquitin mediated proteolysis |
1件: 13 |
270 |
Bg0002 (natalizumab) |
Natalizumab |
D06886 |
1件: ITGA4 |
14件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection |
1件: 13 |
271 |
Bg9418 (interferon beta 1-a) |
Interferon beta-1a |
D04554 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
272 |
Bg9418 (interferon beta-1a) |
Human interferon beta |
- |
- |
- |
2件: 13, 97 |
273 |
Bgg492 |
- |
- |
- |
- |
1件: 13 |
274 |
Bht-3009 |
- |
- |
- |
- |
1件: 13 |
275 |
Bht-3009 0.5 mg |
- |
- |
- |
- |
1件: 13 |
276 |
Bht-3009 1.5 mg |
- |
- |
- |
- |
1件: 13 |
277 |
Bht-3009-01 |
- |
- |
- |
- |
1件: 13 |
278 |
Biib017 |
- |
- |
- |
- |
1件: 13 |
279 |
Biib017 (peginterferon beta-1a) |
- |
- |
- |
- |
1件: 13 |
280 |
Biib019 |
- |
- |
- |
- |
1件: 13 |
281 |
Biib019 (daclizumab) |
Daclizumab |
D03639 |
1件: IL2RA |
11件: Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
1件: 13 |
282 |
Biib033 |
- |
- |
- |
- |
1件: 13 |
283 |
Biib033 (anti-lingo) |
- |
- |
- |
- |
1件: 13 |
284 |
Biib033 (opicinumab) |
Opicinumab |
- |
- |
- |
1件: 13 |
285 |
Biib041 |
- |
- |
- |
- |
1件: 13 |
286 |
Biib041 (fampridine) |
Dalfampridine |
D04127 |
2件: KCNA4, KCND2 |
3件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse |
1件: 13 |
287 |
Biib041 (fampridine-sr) |
Dalfampridine |
D04127 |
2件: KCNA4, KCND2 |
3件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse |
1件: 13 |
288 |
Biib041 (pr fampridine) |
Dalfampridine |
D04127 |
2件: KCNA4, KCND2 |
3件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse |
1件: 13 |
289 |
Biib061 |
- |
- |
- |
- |
1件: 13 |
290 |
Biotin |
Biotin |
D00029 |
- |
- |
3件: 2, 13, 20 |
291 |
Birt 2584 xx |
- |
- |
- |
- |
1件: 13 |
292 |
Bisacodyl |
Bisacodyl |
D00245 |
- |
- |
1件: 13 |
293 |
Blood sample |
- |
- |
- |
- |
12件: 8, 13, 46, 49, 51, 53, 61, 66, 97, 274, 288, 299 |
294 |
Blood samples |
- |
- |
- |
- |
8件: 13, 41, 46, 51, 61, 97, 227, 271 |
295 |
Blood sampling |
- |
- |
- |
- |
4件: 13, 19, 51, 96 |
296 |
Bmmnc |
- |
- |
- |
- |
2件: 13, 57 |
297 |
Bms 188667 (abatacept) |
Abatacept |
D03203 |
2件: CD80, CD86 |
12件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis |
1件: 13 |
298 |
Bone marrow autologous mesenchymal stem cells transplantation |
- |
- |
- |
- |
1件: 13 |
299 |
Borage oil |
Borage oil |
- |
- |
- |
1件: 13 |
300 |
Borage oil 20% gla |
Borage oil |
- |
- |
- |
1件: 13 |
301 |
Bosentan |
Bosentan |
D01227, D07538 |
2件: EDNRA, EDNRB |
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
9件: 13, 41, 47, 51, 84, 85, 86, 88, 210 |
302 |
Boswelan |
- |
- |
- |
- |
1件: 13 |
303 |
Boswellia serrata |
Indian frankincense |
- |
- |
- |
1件: 13 |
304 |
Boswellia serrata extract |
Indian frankincense |
- |
- |
- |
1件: 13 |
305 |
Boswellia serrata extract ps0201bo capsules |
Indian frankincense |
- |
- |
- |
1件: 13 |
306 |
Boswellic acids (boswelan) |
- |
- |
- |
- |
1件: 13 |
307 |
Botox |
Botulinum toxin type a |
D00783 |
1件: SNAP25 |
2件: Insulin secretion, Synaptic vesicle cycle |
4件: 6, 13, 149, 226 |
308 |
Botox® |
- |
- |
- |
- |
1件: 13 |
309 |
Botulinum toxin a |
Botulinum toxin type a |
D00783 |
1件: SNAP25 |
2件: Insulin secretion, Synaptic vesicle cycle |
4件: 13, 51, 149, 226 |
310 |
Botulinum toxin a - haemagglutinin complex |
Botulinum toxin type a |
D00783 |
1件: SNAP25 |
2件: Insulin secretion, Synaptic vesicle cycle |
1件: 13 |
311 |
Botulinum toxin type a |
Botulinum toxin type a |
D00783 |
1件: SNAP25 |
2件: Insulin secretion, Synaptic vesicle cycle |
10件: 2, 5, 6, 7, 13, 15, 17, 70, 113, 149 |
312 |
Bx-1 |
- |
- |
- |
- |
1件: 13 |
313 |
C1-esterase inhibitor (cinryze) |
- |
- |
- |
- |
1件: 13 |
314 |
C105 |
- |
- |
- |
- |
1件: 13 |
315 |
Calcio |
Calcium |
- |
- |
- |
1件: 13 |
316 |
Calcio folinato dc.it |
Calcium |
- |
- |
- |
1件: 13 |
317 |
Calcium |
Calcium |
- |
- |
- |
24件: 6, 13, 19, 46, 49, 51, 65, 68, 75, 79, 84, 93, 94, 95, 96, 97, 214, 215, 222, 224, 235, 265, 298, 299 |
318 |
Calcium carbonate |
Calcium carbonate |
D00932, D10802 |
- |
- |
7件: 13, 19, 46, 75, 96, 235, 299 |
319 |
Calcium levofolinate |
Calcium |
- |
- |
- |
1件: 13 |
320 |
Cannabidiol |
Cannabidiol |
D10915 |
2件: CNR1, CNR2 |
4件: Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis |
13件: 6, 13, 46, 95, 96, 97, 140, 144, 145, 157, 158, 193, 271 |
321 |
Cannabidiol / dronabinol capsule 5 mg+2,5 mg |
Cannabidiol |
D10915 |
2件: CNR1, CNR2 |
4件: Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis |
1件: 13 |
322 |
Cannabidiol capsule 5 mg |
Cannabidiol |
D10915 |
2件: CNR1, CNR2 |
4件: Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis |
1件: 13 |
323 |
Cannabis |
Medical cannabis |
- |
- |
- |
6件: 2, 6, 13, 90, 96, 97 |
324 |
Cannabis based medicine extract (sativex) |
Medical cannabis |
- |
- |
- |
1件: 13 |
325 |
Cannabis, medical |
Medical cannabis |
- |
- |
- |
5件: 2, 6, 13, 96, 97 |
326 |
Cannador |
- |
- |
- |
- |
1件: 13 |
327 |
Caprylic triglyceride |
Tricaprylin |
- |
- |
- |
1件: 13 |
328 |
Capsules with 160 mg teavigo (at least 94% egcg) |
Epigallocatechin gallate |
- |
- |
- |
1件: 13 |
329 |
Carbidopa |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
8件: 2, 4, 6, 13, 17, 90, 164, 201 |
330 |
Carbonate |
Carbonate ion |
- |
- |
- |
10件: 2, 13, 17, 19, 46, 75, 96, 127, 235, 299 |
331 |
Carmustine |
Carmustine |
D00254 |
- |
- |
5件: 11, 13, 14, 28, 60 |
332 |
Carmustine, etoposide, cytarabine, and melphalan (beam) |
Carmustine, Cytarabine |
D00168, D00254, D03046, D03637 |
- |
- |
1件: 13 |
333 |
Carnitine |
Levocarnitine |
D02030, D02176, D04713 |
- |
- |
8件: 5, 13, 58, 96, 97, 265, 298, 316 |
334 |
Carnosine |
Carnosine |
- |
- |
- |
2件: 6, 13 |
335 |
Carnosine, capsulle, 2 g/day, 8 weeks |
Carnosine |
- |
- |
- |
1件: 13 |
336 |
Cci-779 |
- |
- |
- |
- |
2件: 13, 46 |
337 |
Cdp323 |
Cdp323 |
- |
- |
- |
1件: 13 |
338 |
Cellular therapy with ebv specific autologous ctl infusion |
- |
- |
- |
- |
1件: 13 |
339 |
Ceralifimod |
- |
- |
- |
- |
1件: 13 |
340 |
Ceralifmod |
- |
- |
- |
- |
1件: 13 |
341 |
Cesamet™ (nabilone) |
Nabilone |
D05099 |
2件: CNR1, CNR2 |
4件: Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis |
1件: 13 |
342 |
Ceterizine |
- |
- |
- |
- |
1件: 13 |
343 |
Cetirizina |
Cetirizine |
D00664, D07662 |
1件: HRH1 |
3件: Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction |
1件: 13 |
344 |
Cetirizina mylan generics |
Cetirizine |
D00664, D07662 |
1件: HRH1 |
3件: Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction |
1件: 13 |
345 |
Cetirizine |
Cetirizine |
D00664, D07662 |
1件: HRH1 |
3件: Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction |
2件: 13, 35 |
346 |
Cetirizine hydrochloride |
Cetirizine |
D00664, D07662 |
1件: HRH1 |
3件: Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction |
1件: 13 |
347 |
Cgp 77116 |
- |
- |
- |
- |
1件: 13 |
348 |
Charcoal |
Activated charcoal |
D03251 |
- |
- |
1件: 13 |
349 |
Chloride |
Chloride ion |
- |
- |
- |
17件: 6, 11, 13, 14, 34, 46, 51, 96, 97, 127, 168, 193, 227, 228, 288, 297, 299 |
350 |
Cholecalciferol |
Cholecalciferol |
D00188 |
1件: VDR |
4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
9件: 13, 19, 34, 46, 49, 96, 97, 298, 299 |
351 |
Cholecalciferol, vitamin d3 |
Cholecalciferol |
D00188 |
1件: VDR |
4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
1件: 13 |
352 |
Cholestyramine |
Cholestyramine |
- |
- |
- |
2件: 13, 79 |
353 |
Chr-1103 / gbr500 |
- |
- |
- |
- |
1件: 13 |
354 |
Cianocobalamina |
Cyanocobalamin |
D00166, D03615, D03616, D03617 |
- |
- |
1件: 13 |
355 |
Cianocobalamina fu dc.it |
Cyanocobalamin |
D00166, D03615, D03616, D03617 |
- |
- |
1件: 13 |
356 |
Ciclofosfamide |
Cyclophosphamide |
D00287, D07760 |
- |
- |
1件: 13 |
357 |
Circadin |
Melatonin |
D08170 |
2件: MTNR1A, MTNR1B |
2件: Circadian entrainment, Neuroactive ligand-receptor interaction |
1件: 13 |
358 |
Circadin ( inn= melatonin) |
Melatonin |
D08170 |
2件: MTNR1A, MTNR1B |
2件: Circadian entrainment, Neuroactive ligand-receptor interaction |
1件: 13 |
359 |
Cisapride |
Cisapride |
D00274, D02092 |
3件: HTR2A, HTR3A, HTR4 |
7件: Calcium signaling pathway, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Serotonergic synapse, Taste transduction, cAMP signaling pathway |
1件: 13 |
360 |
Cladribine |
Cladribine |
D01370 |
1件: RRM1 |
5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
2件: 13, 94 |
361 |
Cladribine 3.5 mg/kg |
Cladribine |
D01370 |
1件: RRM1 |
5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
1件: 13 |
362 |
Cladribine 5.25 mg/kg |
Cladribine |
D01370 |
1件: RRM1 |
5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
1件: 13 |
363 |
Cladribine tablets |
Cladribine |
D01370 |
1件: RRM1 |
5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
1件: 13 |
364 |
Clemastine |
Clemastine |
D00666, D03535 |
1件: HRH1 |
3件: Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction |
1件: 13 |
365 |
Clostridium botulinum |
Clostridium botulinum |
- |
- |
- |
1件: 13 |
366 |
Clostridium botulinum toxin type a |
Botulinum toxin type a |
D00783 |
1件: SNAP25 |
2件: Insulin secretion, Synaptic vesicle cycle |
1件: 13 |
367 |
Cnm-au8 |
- |
- |
- |
- |
2件: 2, 13 |
368 |
Cnp-ms-0601 |
- |
- |
- |
- |
1件: 13 |
369 |
Cnto 1275 |
Ustekinumab |
D09214 |
3件: IL12A, IL12B, IL23A |
25件: African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease (IBD), Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus |
2件: 13, 96 |
370 |
Co-14 |
- |
- |
- |
- |
1件: 13 |
371 |
Coconut |
Coconut |
- |
- |
- |
1件: 13 |
372 |
Coconut oil |
Coconut oil |
D05326 |
- |
- |
1件: 13 |
373 |
Coconut oil and epigallocatechin gallate |
Epigallocatechin gallate |
- |
- |
- |
1件: 13 |
374 |
Coenzyme q |
- |
- |
- |
- |
1件: 13 |
375 |
Colecalciferol |
Cholecalciferol |
D00188 |
1件: VDR |
4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
4件: 13, 46, 96, 228 |
376 |
Colecalciferol concentrate (oily form) |
Cholecalciferol |
D00188 |
1件: VDR |
4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
1件: 13 |
377 |
Control |
Chloroxylenol |
D03473 |
- |
- |
4件: 6, 13, 46, 168 |
378 |
Cop-1 |
Glatiramer |
D04318 |
20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G |
32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease (IBD), Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
1件: 13 |
379 |
Cop-1/copolymer-1 |
Glatiramer |
D04318 |
20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G |
32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease (IBD), Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
1件: 13 |
380 |
Copaxone |
Glatiramer |
D04318 |
20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G |
32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease (IBD), Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
1件: 13 |
381 |
Copaxone 20 mg/ml |
Glatiramer |
D04318 |
20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G |
32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease (IBD), Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
1件: 13 |
382 |
Copaxone 20 mg/ml solution for injection, pre-filled syringe |
Glatiramer |
D04318 |
20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G |
32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease (IBD), Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
1件: 13 |
383 |
Copaxone 40 mg/ml solution for injection, pre-filled syringe |
Glatiramer |
D04318 |
20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G |
32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease (IBD), Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
1件: 13 |
384 |
Copaxone subcutaneous injection syringe |
- |
- |
- |
- |
1件: 13 |
385 |
Copaxone-teva |
- |
- |
- |
- |
1件: 13 |
386 |
Copaxone® |
- |
- |
- |
- |
1件: 13 |
387 |
Copolymer 1 |
Glatiramer |
D04318 |
20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G |
32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease (IBD), Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
1件: 13 |
388 |
Copolymer-1 |
Glatiramer |
D04318 |
20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G |
32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease (IBD), Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
1件: 13 |
389 |
Corticosteroid |
- |
- |
- |
- |
10件: 13, 42, 43, 44, 45, 66, 84, 96, 97, 222 |
390 |
Corticosteroids & tancart19/20 |
- |
- |
- |
- |
1件: 13 |
391 |
Corticotropin |
Corticotropin |
D00146 |
1件: MC2R |
5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
7件: 2, 13, 46, 75, 78, 84, 222 |
392 |
Cranberry |
Cranberry |
- |
- |
- |
1件: 13 |
393 |
Creatine |
Creatine |
- |
- |
- |
12件: 1, 2, 5, 6, 8, 13, 46, 49, 50, 113, 156, 201 |
394 |
Cs-0777 tablets |
- |
- |
- |
- |
1件: 13 |
395 |
Curcumin |
Curcumin |
- |
- |
- |
10件: 13, 46, 49, 67, 74, 94, 96, 97, 139, 299 |
396 |
Cyclophosfamide |
- |
- |
- |
- |
1件: 13 |
397 |
Cyclophosphamide |
Cyclophosphamide |
D00287, D07760 |
- |
- |
43件: 13, 14, 16, 19, 20, 26, 28, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 56, 60, 61, 62, 65, 66, 84, 85, 93, 96, 162, 164, 172, 222, 224, 265, 274, 283, 284, 285, 288, 326, 331 |
398 |
Cyclophosphamide (drug) |
Cyclophosphamide |
D00287, D07760 |
- |
- |
1件: 13 |
399 |
Cyclophosphamide and atg |
Cyclophosphamide |
D00287, D07760 |
- |
- |
1件: 13 |
400 |
Cyclophosphamide monohydrate |
Cyclophosphamide |
D00287, D07760 |
- |
- |
2件: 13, 60 |
401 |
Cyclophosphamide/glatiramer acetate |
Cyclophosphamide |
D00287, D07760 |
- |
- |
1件: 13 |
402 |
Cymbalta |
Duloxetine |
D01179, D07880 |
2件: SLC6A2, SLC6A4 |
2件: Serotonergic synapse, Synaptic vesicle cycle |
3件: 6, 13, 49 |
403 |
Cysteine |
L-cysteine |
D00026, D02326 |
- |
- |
9件: 6, 13, 19, 84, 85, 88, 90, 254, 296 |
404 |
Cytarabine |
Cytarabine |
D00168, D03046, D03637 |
- |
- |
6件: 11, 13, 14, 25, 49, 60 |
405 |
Cytolytic cd4+ t cells |
- |
- |
- |
- |
1件: 13 |
406 |
Células madre mesenquimales |
- |
- |
- |
- |
1件: 13 |
407 |
D mannose |
Mannose |
- |
- |
- |
1件: 13 |
408 |
D-aspartate |
D-aspartic acid |
- |
- |
- |
1件: 13 |
409 |
D-biotin |
Biotin |
D00029 |
- |
- |
2件: 13, 20 |
410 |
Dac-hyp |
- |
- |
- |
- |
1件: 13 |
411 |
Daclizumab |
Daclizumab |
D03639 |
1件: IL2RA |
11件: Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
7件: 13, 56, 60, 65, 97, 283, 284 |
412 |
Daclizumab (anti-cd25 humanized monoclonal antibody) |
Daclizumab |
D03639 |
1件: IL2RA |
11件: Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
1件: 13 |
413 |
Daclizumab high yield process |
Daclizumab |
D03639 |
1件: IL2RA |
11件: Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
1件: 13 |
414 |
Daclizumab hyp |
Daclizumab |
D03639 |
1件: IL2RA |
11件: Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
1件: 13 |
415 |
Daclizumab hyp (dac hyp) |
Daclizumab |
D03639 |
1件: IL2RA |
11件: Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
1件: 13 |
416 |
Daclizumab with greek suufix |
Daclizumab |
D03639 |
1件: IL2RA |
11件: Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
1件: 13 |
417 |
Dalfampridine |
Dalfampridine |
D04127 |
2件: KCNA4, KCND2 |
3件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse |
2件: 4, 13 |
418 |
Dalfampridine er |
Dalfampridine |
D04127 |
2件: KCNA4, KCND2 |
3件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse |
1件: 13 |
419 |
Dalfampridine-er 10mg |
Dalfampridine |
D04127 |
2件: KCNA4, KCND2 |
3件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse |
1件: 13 |
420 |
Dalfampridine-er 5mg |
Dalfampridine |
D04127 |
2件: KCNA4, KCND2 |
3件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse |
1件: 13 |
421 |
Darifenacin |
Darifenacin |
D01699, D03654 |
1件: CHRM3 |
9件: Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, Pancreatic secretion, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction |
2件: 6, 13 |
422 |
Dc-tab |
- |
- |
- |
- |
1件: 13 |
423 |
Dekristol |
- |
- |
- |
- |
2件: 13, 97 |
424 |
Dekristol 20000 ie |
- |
- |
- |
- |
1件: 13 |
425 |
Dekristol® 400-tabletten |
- |
- |
- |
- |
1件: 13 |
426 |
Dekristol®-tablette 1 (400 ie) |
- |
- |
- |
- |
1件: 13 |
427 |
Delta-9-tetrahydrocannabinol |
Dronabinol |
D00306 |
2件: CNR1, CNR2 |
4件: Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis |
1件: 13 |
428 |
Demestril septem |
- |
- |
- |
- |
1件: 13 |
429 |
Dexamethason |
- |
- |
- |
- |
3件: 13, 46, 331 |
430 |
Dexamethasone |
Dexamethasone |
D00292, D00975, D01510, D01615, D01632, D01948, D02174, D02591, D02592 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
20件: 13, 16, 28, 35, 46, 53, 63, 65, 70, 74, 75, 81, 83, 84, 90, 96, 97, 222, 296, 299 |
431 |
Dexamethasone soduim phosphate |
Dexamethasone |
D00292, D00975, D01510, D01615, D01632, D01948, D02174, D02591, D02592 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 13 |
432 |
Dexchlorpheniramine |
Dexchlorpheniramine |
D07803 |
1件: HRH1 |
3件: Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction |
1件: 13 |
433 |
Dexrazoxane |
Dexrazoxane |
D03730 |
2件: TOP2A, TOP2B |
1件: Platinum drug resistance |
1件: 13 |
434 |
Dexrazoxane (drz) plus mitoxantrone (mx) |
Mitoxantrone |
D02166, D08224 |
2件: TOP2A, TOP2B |
1件: Platinum drug resistance |
1件: 13 |
435 |
Dextromethorphan |
Dextromethorphan |
D00848, D03742, D03744 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
9件: 2, 6, 8, 13, 46, 78, 96, 97, 156 |
436 |
Dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg |
Dextromethorphan |
D00848, D03742, D03744 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
2件: 2, 13 |
437 |
Dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg |
Dextromethorphan |
D00848, D03742, D03744 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
2件: 2, 13 |
438 |
Dibase |
- |
- |
- |
- |
1件: 13 |
439 |
Diclofenac |
Diclofenac |
D00903, D00904, D07816 |
2件: PTGS1, PTGS2 |
21件: Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
4件: 13, 34, 46, 271 |
440 |
Diclofenac sodium topical gel |
Diclofenac |
D00903, D00904, D07816 |
2件: PTGS1, PTGS2 |
21件: Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
1件: 13 |
441 |
Dimethyl fumarate |
Dimethyl fumarate |
D03846 |
1件: KEAP1 |
4件: Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Pathways in cancer, Ubiquitin mediated proteolysis |
3件: 13, 51, 86 |
442 |
Dimethyl fumarate (dmf) |
Dimethyl fumarate |
D03846 |
1件: KEAP1 |
4件: Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Pathways in cancer, Ubiquitin mediated proteolysis |
3件: 13, 51, 86 |
443 |
Dimethyl fumarate [dmf] |
Dimethyl fumarate |
D03846 |
1件: KEAP1 |
4件: Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Pathways in cancer, Ubiquitin mediated proteolysis |
1件: 13 |
444 |
Dimetilfumarato |
- |
- |
- |
- |
1件: 13 |
445 |
Diphenydramine |
- |
- |
- |
- |
1件: 13 |
446 |
Diroximel fumarate |
Diroximel fumarate |
D11154 |
- |
- |
1件: 13 |
447 |
Diroximel fumarate (drf) |
Diroximel fumarate |
D11154 |
- |
- |
1件: 13 |
448 |
Dirucotide |
Dirucotide |
D09396 |
- |
- |
1件: 13 |
449 |
Dirucotide acetate |
Dirucotide |
D09396 |
- |
- |
1件: 13 |
450 |
Discontinuation of disease modifying therapy |
- |
- |
- |
- |
1件: 13 |
451 |
Disease modifying therapy |
- |
- |
- |
- |
1件: 13 |
452 |
Dmt continuation |
- |
- |
- |
- |
1件: 13 |
453 |
Domperidone |
Domperidone |
D01745, D07868 |
1件: DRD2 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
5件: 6, 13, 17, 51, 230 |
454 |
Donepezil |
Donepezil |
D00670, D07869 |
1件: ACHE |
2件: Cholinergic synapse, Glycerophospholipid metabolism |
9件: 5, 6, 13, 46, 78, 124, 127, 156, 206 |
455 |
Donepezil hci (drug) |
Donepezil |
D00670, D07869 |
1件: ACHE |
2件: Cholinergic synapse, Glycerophospholipid metabolism |
1件: 13 |
456 |
Dotarem 0,5mmol/ml, |
Gadoteric acid |
D08007 |
- |
- |
1件: 13 |
457 |
Doxycycline |
Doxycycline |
D00307, D02129, D03903, D03904, D07876 |
- |
- |
15件: 13, 23, 28, 46, 84, 85, 89, 96, 97, 158, 162, 167, 227, 280, 299 |
458 |
Dpa-714 pet/mri |
- |
- |
- |
- |
1件: 13 |
459 |
Dronabinol |
Dronabinol |
D00306 |
2件: CNR1, CNR2 |
4件: Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis |
5件: 2, 13, 46, 271, 298 |
460 |
Dronabinol capsule 2,5 mg |
Dronabinol |
D00306 |
2件: CNR1, CNR2 |
4件: Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis |
1件: 13 |
461 |
Dtpa |
Pentetic acid |
D05422 |
- |
- |
3件: 13, 28, 299 |
462 |
Duloxetine |
Duloxetine |
D01179, D07880 |
2件: SLC6A2, SLC6A4 |
2件: Serotonergic synapse, Synaptic vesicle cycle |
2件: 6, 13 |
463 |
Duloxetine hydrochloride (hci) |
Duloxetine |
D01179, D07880 |
2件: SLC6A2, SLC6A4 |
2件: Serotonergic synapse, Synaptic vesicle cycle |
1件: 13 |
464 |
Dydrogesterone |
Dydrogesterone |
D01217 |
1件: PGR |
4件: Breast cancer, Estrogen signaling pathway, Oocyte meiosis, Progesterone-mediated oocyte maturation |
1件: 13 |
465 |
Dysport |
Botulinum toxin type a |
D00783 |
1件: SNAP25 |
2件: Insulin secretion, Synaptic vesicle cycle |
2件: 13, 36 |
466 |
Dysport® |
- |
- |
- |
- |
1件: 13 |
467 |
Early highly effective therapies group |
- |
- |
- |
- |
1件: 13 |
468 |
Ebixa |
Memantine |
D04905, D08174 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
3件: 2, 6, 13 |
469 |
Ecp002a |
- |
- |
- |
- |
1件: 13 |
470 |
Eculizumab |
Eculizumab |
D03940 |
1件: C5 |
7件: Complement and coagulation cascades, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Pertussis, Prion diseases, Staphylococcus aureus infection, Systemic lupus erythematosus |
7件: 11, 13, 14, 62, 109, 222, 223 |
471 |
Efalizumab |
Efalizumab |
D03959 |
1件: ITGAL |
11件: Cell adhesion molecules (CAMs), Epstein-Barr virus infection, Human T-cell leukemia virus 1 infection, Leukocyte transendothelial migration, Malaria, Natural killer cell mediated cytotoxicity, Rap1 signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Staphylococcus aureus infection, Viral myocarditis |
8件: 11, 13, 37, 46, 53, 61, 95, 96 |
472 |
Egb 761® (tanakan®) |
Ginkgo biloba |
- |
- |
- |
1件: 13 |
473 |
Egcg |
Epigallocatechin gallate |
- |
- |
- |
8件: 6, 13, 17, 28, 85, 113, 206, 299 |
474 |
Ek-12 |
- |
- |
- |
- |
1件: 13 |
475 |
Elezanumab |
Elezanumab |
D11355 |
1件: RGMA |
2件: Axon guidance, TGF-beta signaling pathway |
1件: 13 |
476 |
Elnd002 |
- |
- |
- |
- |
1件: 13 |
477 |
Emselex 15 mg retardtabletten |
- |
- |
- |
- |
1件: 13 |
478 |
Emselex 7,5 mg retardtabletten |
- |
- |
- |
- |
1件: 13 |
479 |
Ena713 |
Rivastigmine |
D02558, D03822 |
1件: ACHE |
2件: Cholinergic synapse, Glycerophospholipid metabolism |
1件: 13 |
480 |
Encapsulated simvastatin tablets |
Simvastatin |
D00434 |
1件: HMGCR |
4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
1件: 13 |
481 |
Endoxan |
- |
- |
- |
- |
2件: 13, 28 |
482 |
Endoxan - ciclofosfamide |
Cyclophosphamide |
D00287, D07760 |
- |
- |
1件: 13 |
483 |
Endoxan baxter |
- |
- |
- |
- |
1件: 13 |
484 |
Enriched hematopoetic stem cell infusion |
- |
- |
- |
- |
3件: 13, 19, 284 |
485 |
Eparmefolin 30 cpr 0,1/0,5mg |
- |
- |
- |
- |
1件: 13 |
486 |
Epigallocatechin |
Epigallocatechin |
- |
- |
- |
4件: 13, 28, 85, 113 |
487 |
Epigallocatechin gallate |
Epigallocatechin gallate |
- |
- |
- |
1件: 13 |
488 |
Epoetin alfa |
Erythropoietin |
D03231 |
1件: EPOR |
5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
2件: 13, 46 |
489 |
Epoetin beta |
Erythropoietin |
D03231 |
1件: EPOR |
5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
1件: 13 |
490 |
Erypo/erypo fs |
- |
- |
- |
- |
1件: 13 |
491 |
Erythropoietin |
Erythropoietin |
D03231 |
1件: EPOR |
5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
8件: 2, 6, 13, 22, 47, 70, 95, 96 |
492 |
Escalation therapies group |
- |
- |
- |
- |
1件: 13 |
493 |
Escitalopram |
Escitalopram |
D02567, D07704, D07913 |
1件: SLC6A4 |
2件: Serotonergic synapse, Synaptic vesicle cycle |
3件: 2, 6, 13 |
494 |
Escitalopram oxalate antidepressant |
Escitalopram |
D02567, D07704, D07913 |
1件: SLC6A4 |
2件: Serotonergic synapse, Synaptic vesicle cycle |
1件: 13 |
495 |
Essential - hydroxytyrosol |
Hydroxytyrosol |
- |
- |
- |
1件: 13 |
496 |
Essential fatty acids |
- |
- |
- |
- |
1件: 13 |
497 |
Estradiol |
Estradiol |
D00105, D01413, D01617, D01953, D04061, D04063, D04064, D04065 |
2件: ESR1, ESR2 |
9件: Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway |
5件: 13, 46, 49, 226, 299 |
498 |
Estradiol hemihydrate |
Estradiol |
D00105, D01413, D01617, D01953, D04061, D04063, D04064, D04065 |
2件: ESR1, ESR2 |
9件: Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway |
1件: 13 |
499 |
Estriol |
Estriol |
D00185, D01986 |
2件: ESR1, ESR2 |
9件: Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway |
2件: 13, 227 |
500 |
Estroprogestins |
- |
- |
- |
- |
1件: 13 |
501 |
Eszopiclone |
Eszopiclone |
D02624 |
16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
3件: 6, 13, 46 |
502 |
Ethinylestradiol |
Ethinylestradiol |
D00554 |
1件: ESR1 |
8件: Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway |
1件: 13 |
503 |
Etifoxine |
Etifoxine |
D07320 |
- |
- |
1件: 13 |
504 |
Etims |
- |
- |
- |
- |
1件: 13 |
505 |
Etims (edc-fixed autologous pbmcs coupled with 7 immunodominant myelin peptides in ms patients) |
- |
- |
- |
- |
1件: 13 |
506 |
Etoposide |
Etoposide |
D00125, D04107 |
2件: TOP2A, TOP2B |
1件: Platinum drug resistance |
11件: 11, 13, 14, 26, 28, 34, 60, 65, 85, 164, 331 |
507 |
Eu/1/08/454/001-002, eu/1/08/454/005-007 |
- |
- |
- |
- |
1件: 13 |
508 |
Eu/1/95/003/005-010 |
- |
- |
- |
- |
1件: 13 |
509 |
Eu/1/97/033/002 |
- |
- |
- |
- |
1件: 13 |
510 |
Eu/1/98/063/001-003 |
- |
- |
- |
- |
1件: 13 |
511 |
Eu/1/98/063/004-006 |
- |
- |
- |
- |
1件: 13 |
512 |
Evobrutinib |
Evobrutinib |
- |
- |
- |
3件: 13, 46, 49 |
513 |
Exelon |
Rivastigmine |
D02558, D03822 |
1件: ACHE |
2件: Cholinergic synapse, Glycerophospholipid metabolism |
2件: 6, 13 |
514 |
Exelon transdermales pflaster |
Rivastigmine |
D02558, D03822 |
1件: ACHE |
2件: Cholinergic synapse, Glycerophospholipid metabolism |
1件: 13 |
515 |
Experimental glatiramer acetate |
Glatiramer |
D04318 |
20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G |
32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease (IBD), Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
1件: 13 |
516 |
Extavia |
Interferon beta-1b |
D00746 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
517 |
Extavia (interferon beta-1b), novartis pharma ag |
Human interferon beta |
- |
- |
- |
1件: 13 |
518 |
Extavia 250 microgram/ml |
Interferon beta-1b |
D00746 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
519 |
Extavia 250 micrograms/ml |
Interferon beta-1b |
D00746 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
520 |
Extavia*sc 15fl 250mcg/ml+15si |
Interferon beta-1b |
D00746 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
521 |
Extavia® |
- |
- |
- |
- |
1件: 13 |
522 |
Extended release fampridine |
Dalfampridine |
D04127 |
2件: KCNA4, KCND2 |
3件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse |
1件: 13 |
523 |
Extended-release oxycodone |
Oxycodone |
D03783, D05312, D05462 |
3件: OPRD1, OPRK1, OPRM1 |
5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
1件: 13 |
524 |
Extended-release quetiapine fumarate |
Quetiapine |
D00458, D08456 |
2件: DRD2, HTR2A |
11件: Alcoholism, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Serotonergic synapse, cAMP signaling pathway |
1件: 13 |
525 |
F-18 fedaa1106 (bay85-8101) |
- |
- |
- |
- |
1件: 13 |
526 |
Fampridine |
Dalfampridine |
D04127 |
2件: KCNA4, KCND2 |
3件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse |
1件: 13 |
527 |
Fampridine sr |
Dalfampridine |
D04127 |
2件: KCNA4, KCND2 |
3件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse |
1件: 13 |
528 |
Fampridine-sr |
Dalfampridine |
D04127 |
2件: KCNA4, KCND2 |
3件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse |
1件: 13 |
529 |
Fampridine-sr b.i.d. (twice daily) |
Dalfampridine |
D04127 |
2件: KCNA4, KCND2 |
3件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse |
1件: 13 |
530 |
Fampyra |
Dalfampridine |
D04127 |
2件: KCNA4, KCND2 |
3件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse |
1件: 13 |
531 |
Fampyra 10 mg prolonged-release tablets |
Dalfampridine |
D04127 |
2件: KCNA4, KCND2 |
3件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse |
1件: 13 |
532 |
Fampyra 10mg prolonged release tablets |
Dalfampridine |
D04127 |
2件: KCNA4, KCND2 |
3件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse |
1件: 13 |
533 |
Febuxostat |
Febuxostat |
D01206 |
1件: XDH |
5件: Caffeine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Peroxisome, Purine metabolism |
3件: 2, 6, 13 |
534 |
Fecal microbial transplant (fmt) |
- |
- |
- |
- |
1件: 13 |
535 |
Fecal microbial transplants |
- |
- |
- |
- |
1件: 13 |
536 |
Fecal microbiota |
- |
- |
- |
- |
2件: 13, 97 |
537 |
Femoston 1/10 |
- |
- |
- |
- |
1件: 13 |
538 |
Femoston 2/10 |
- |
- |
- |
- |
1件: 13 |
539 |
Feraheme |
Ferumoxytol |
D04177 |
- |
- |
1件: 13 |
540 |
Ferumoxytol |
Ferumoxytol |
D04177 |
- |
- |
1件: 13 |
541 |
Filgrastim |
Filgrastim |
D03235 |
1件: CSF3R |
5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
25件: 2, 6, 13, 25, 26, 28, 34, 35, 40, 41, 42, 45, 46, 49, 51, 60, 62, 65, 96, 113, 164, 283, 284, 285, 331 |
542 |
Fingolimob (fty) |
- |
- |
- |
- |
1件: 13 |
543 |
Fingolimod |
Fingolimod |
D10001 |
1件: S1PR1 |
3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway |
3件: 13, 14, 156 |
544 |
Fingolimod (fty720) |
Fingolimod |
D10001 |
1件: S1PR1 |
3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway |
2件: 13, 156 |
545 |
Fingolimod 0.5 mg |
Fingolimod |
D10001 |
1件: S1PR1 |
3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway |
1件: 13 |
546 |
Fingolimod 1.25 mg |
Fingolimod |
D10001 |
1件: S1PR1 |
3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway |
1件: 13 |
547 |
Fingolimod hydrochloride |
Fingolimod |
D10001 |
1件: S1PR1 |
3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway |
1件: 13 |
548 |
Fingolimodi |
- |
- |
- |
- |
1件: 13 |
549 |
Fingolmod |
- |
- |
- |
- |
1件: 13 |
550 |
Firategrast |
Firategrast |
D06590 |
1件: ITGA4 |
14件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection |
1件: 13 |
551 |
Firategrast (usan approved name) |
Firategrast |
D06590 |
1件: ITGA4 |
14件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection |
1件: 13 |
552 |
Firategrast 150 mg |
Firategrast |
D06590 |
1件: ITGA4 |
14件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection |
1件: 13 |
553 |
Firategrast 300 mg |
Firategrast |
D06590 |
1件: ITGA4 |
14件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection |
1件: 13 |
554 |
Firategrast gastro-retentive solution |
Firategrast |
D06590 |
1件: ITGA4 |
14件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection |
1件: 13 |
555 |
Firategrast immediate release tablet |
Firategrast |
D06590 |
1件: ITGA4 |
14件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection |
1件: 13 |
556 |
Firategrast modified release tablet |
Firategrast |
D06590 |
1件: ITGA4 |
14件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection |
1件: 13 |
557 |
Fish oil |
Fish oil |
- |
- |
- |
7件: 13, 46, 49, 66, 96, 260, 299 |
558 |
Fish oil concentrate |
Fish oil |
- |
- |
- |
1件: 13 |
559 |
Fish oil, rich in omega-3-acids |
Fish oil |
- |
- |
- |
1件: 13 |
560 |
Fish oil,rich in omega 3 acids |
Fish oil |
- |
- |
- |
1件: 13 |
561 |
Fludara |
Fludarabine |
D01907, D07966 |
1件: RRM1 |
5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
1件: 13 |
562 |
Fludarabine |
Fludarabine |
D01907, D07966 |
1件: RRM1 |
5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
17件: 13, 28, 36, 46, 49, 51, 60, 61, 62, 65, 85, 96, 164, 283, 284, 285, 326 |
563 |
Flumazenil |
Flumazenil |
D00697 |
16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
5件: 6, 13, 17, 18, 206 |
564 |
Fluoxetin |
Fluoxetine |
D00326, D00823 |
1件: SLC6A4 |
2件: Serotonergic synapse, Synaptic vesicle cycle |
3件: 13, 179, 206 |
565 |
Fluoxetin hexal |
Fluoxetine |
D00326, D00823 |
1件: SLC6A4 |
2件: Serotonergic synapse, Synaptic vesicle cycle |
1件: 13 |
566 |
Fluoxetine |
Fluoxetine |
D00326, D00823 |
1件: SLC6A4 |
2件: Serotonergic synapse, Synaptic vesicle cycle |
4件: 13, 17, 78, 86 |
567 |
Fluoxetine hydrochloride |
Fluoxetine |
D00326, D00823 |
1件: SLC6A4 |
2件: Serotonergic synapse, Synaptic vesicle cycle |
1件: 13 |
568 |
Flupirtin |
- |
- |
- |
- |
1件: 13 |
569 |
Flupirtine |
Flupirtine |
D07978 |
- |
- |
1件: 13 |
570 |
Flupirtinmaleat |
- |
- |
- |
- |
1件: 13 |
571 |
Flurbiprofen |
Flurbiprofen |
D00330, D01475, D02290 |
2件: PTGS1, PTGS2 |
21件: Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
2件: 13, 46 |
572 |
Fmp30 donor stool |
- |
- |
- |
- |
1件: 13 |
573 |
Folate |
Folic acid |
D00070 |
- |
- |
3件: 13, 46, 49 |
574 |
Folatescan (technetium tc 99mec20) |
- |
- |
- |
- |
4件: 13, 46, 49, 96 |
575 |
Formulation a |
- |
- |
- |
- |
1件: 13 |
576 |
Formulation b |
- |
- |
- |
- |
1件: 13 |
577 |
Formulation c |
- |
- |
- |
- |
1件: 13 |
578 |
Formulation d |
- |
- |
- |
- |
1件: 13 |
579 |
Freshly-pressed extra virgin olive oil |
Olive oil |
D03311 |
- |
- |
1件: 13 |
580 |
Fty720 |
- |
- |
- |
- |
2件: 13, 14 |
581 |
Fty720d |
- |
- |
- |
- |
1件: 13 |
582 |
Full spectrum vitamin |
- |
- |
- |
- |
1件: 13 |
583 |
Fully humanized anti-human il-6 receptor (il-6r) neutralizing monoclonal antibody |
- |
- |
- |
- |
1件: 13 |
584 |
Fumaric acid |
Fumaric acid |
D02308 |
- |
- |
1件: 13 |
585 |
G-csf |
Filgrastim |
D03235 |
1件: CSF3R |
5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
12件: 6, 13, 16, 49, 51, 60, 65, 85, 96, 284, 285, 331 |
586 |
G2-sfm (ifn-beta-1a from clone 484-39,fbs-free process) |
- |
- |
- |
- |
1件: 13 |
587 |
Ga 20 mg/ml |
- |
- |
- |
- |
1件: 13 |
588 |
Ga 40 mg/ml |
- |
- |
- |
- |
1件: 13 |
589 |
Ga depot |
- |
- |
- |
- |
1件: 13 |
590 |
Ga depot 40 mg |
- |
- |
- |
- |
1件: 13 |
591 |
Ga depot 40mg once monthly |
- |
- |
- |
- |
1件: 13 |
592 |
Ga depot 80 mg |
- |
- |
- |
- |
1件: 13 |
593 |
Gabapentin |
Gabapentin |
D00332 |
5件: CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, SLC6A1 |
9件: Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cardiac muscle contraction, Dilated cardiomyopathy (DCM), GABAergic synapse, Hypertrophic cardiomyopathy (HCM), MAPK signaling pathway, Oxytocin signaling pathway, Synaptic vesicle cycle |
5件: 6, 13, 19, 70, 298 |
594 |
Gabapentine |
Gabapentin |
D00332 |
5件: CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, SLC6A1 |
9件: Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cardiac muscle contraction, Dilated cardiomyopathy (DCM), GABAergic synapse, Hypertrophic cardiomyopathy (HCM), MAPK signaling pathway, Oxytocin signaling pathway, Synaptic vesicle cycle |
1件: 13 |
595 |
Gabapentine 300mg |
Gabapentin |
D00332 |
5件: CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, SLC6A1 |
9件: Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cardiac muscle contraction, Dilated cardiomyopathy (DCM), GABAergic synapse, Hypertrophic cardiomyopathy (HCM), MAPK signaling pathway, Oxytocin signaling pathway, Synaptic vesicle cycle |
1件: 13 |
596 |
Gadobenate |
Gadobenic acid |
D04283, D08018 |
- |
- |
1件: 13 |
597 |
Gadobenate dimeglumine |
Gadobenic acid |
D04283, D08018 |
- |
- |
1件: 13 |
598 |
Gadobutrol |
Gadobutrol |
D07420 |
- |
- |
3件: 13, 22, 46 |
599 |
Gadolinium |
Gadolinium |
- |
- |
- |
6件: 13, 34, 46, 58, 65, 305 |
600 |
Gadolinium-based contrast |
Gadolinium |
- |
- |
- |
1件: 13 |
601 |
Gadoteric acid |
Gadoteric acid |
D08007 |
- |
- |
1件: 13 |
602 |
Gadoteridol |
Gadoteridol |
D01137 |
- |
- |
1件: 13 |
603 |
Gadovist 1 mmol/ml solución inyectable en jeringa precargada/ cartucho precargado |
- |
- |
- |
- |
1件: 13 |
604 |
Gadovist 1.0 mmol/ml injektionslösung |
- |
- |
- |
- |
1件: 13 |
605 |
Gamma-tocopherol |
Tocopherol |
D02332 |
- |
- |
1件: 13 |
606 |
Gd-dtpa-st |
Pentetic acid |
D05422 |
- |
- |
1件: 13 |
607 |
Genotropin |
Somatotropin |
D02691 |
1件: GHR |
5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
3件: 13, 78, 193 |
608 |
Gilenya |
Fingolimod |
D10001 |
1件: S1PR1 |
3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway |
2件: 2, 13 |
609 |
Gilenya / imusera |
Fingolimod |
D10001 |
1件: S1PR1 |
3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway |
1件: 13 |
610 |
Gilenya® |
Fingolimod |
D10001 |
1件: S1PR1 |
3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway |
1件: 13 |
611 |
Gileyna |
- |
- |
- |
- |
1件: 13 |
612 |
Ginkgo |
Ginkgo biloba |
- |
- |
- |
3件: 6, 13, 90 |
613 |
Ginkgo biloba |
Ginkgo biloba |
- |
- |
- |
2件: 13, 90 |
614 |
Ginseng |
Ginseng |
D06772 |
- |
- |
3件: 13, 46, 53 |
615 |
Glatiramer |
Glatiramer |
D04318 |
20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G |
32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease (IBD), Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
4件: 2, 13, 96, 156 |
616 |
Glatiramer acetate |
Glatiramer |
D04318 |
20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G |
32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease (IBD), Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
3件: 13, 96, 156 |
617 |
Glatiramer acetate (db) |
Glatiramer |
D04318 |
20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G |
32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease (IBD), Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
1件: 13 |
618 |
Glatiramer acetate (ga) |
Glatiramer |
D04318 |
20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G |
32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease (IBD), Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
1件: 13 |
619 |
Glatiramer acetate (ga) 40 mg |
Glatiramer |
D04318 |
20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G |
32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease (IBD), Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
1件: 13 |
620 |
Glatiramer acetate (ol) |
Glatiramer |
D04318 |
20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G |
32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease (IBD), Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
1件: 13 |
621 |
Glatiramer acetate 150mg enteric coated tablets |
Glatiramer |
D04318 |
20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G |
32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease (IBD), Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
1件: 13 |
622 |
Glatiramer acetate 150mg enteric-coated (gastro-resistant) tablets |
Glatiramer |
D04318 |
20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G |
32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease (IBD), Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
1件: 13 |
623 |
Glatiramer acetate 20 mg |
Glatiramer |
D04318 |
20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G |
32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease (IBD), Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
1件: 13 |
624 |
Glatiramer acetate 20 mg, with mitoxantrone |
Mitoxantrone |
D02166, D08224 |
2件: TOP2A, TOP2B |
1件: Platinum drug resistance |
1件: 13 |
625 |
Glatiramer acetate 20 mg/0.5 ml |
Glatiramer |
D04318 |
20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G |
32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease (IBD), Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
1件: 13 |
626 |
Glatiramer acetate 40 mg |
Glatiramer |
D04318 |
20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G |
32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease (IBD), Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
1件: 13 |
627 |
Glatiramer acetate injection with oral cetirizine hydrochloride |
Cetirizine, Glatiramer |
D00664, D04318, D07662 |
21件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G, HRH1 |
35件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Calcium signaling pathway, Cell adhesion molecules (CAMs), Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease (IBD), Inflammatory mediator regulation of TRP channels, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Neuroactive ligand-receptor interaction, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
1件: 13 |
628 |
Glatiramer acetate with minocycline |
Minocycline |
D00850, D05045 |
- |
- |
1件: 13 |
629 |
Glatiramer acetate, (copaxone®) |
Glatiramer |
D04318 |
20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G |
32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease (IBD), Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
1件: 13 |
630 |
Glatiramer acetate, ifn-beta 1a (im), ifn-beta 1a (subcutaneous), and ifn-beta 1b |
Glatiramer |
D04318 |
20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G |
32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease (IBD), Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
1件: 13 |
631 |
Glatiramer acetate, n-acetylcysteine |
Acetylcysteine |
D00221 |
- |
- |
1件: 13 |
632 |
Glucose |
D-glucose |
D00009 |
- |
- |
3件: 6, 13, 299 |
633 |
Glutamate |
Glutamic acid |
D00007, D04341 |
- |
- |
1件: 13 |
634 |
Glutamate and aspartate |
Aspartic acid, Glutamic acid |
D00007, D00013, D04341 |
- |
- |
1件: 13 |
635 |
Glycerol |
Glycerin |
D00028 |
- |
- |
4件: 6, 13, 316, 317 |
636 |
Glycerol-1,3-didecanoate-2-octadeca-(6z,9z,12z)-trienoate |
Glycerin |
D00028 |
- |
- |
1件: 13 |
637 |
Gnbac1 |
- |
- |
- |
- |
1件: 13 |
638 |
Gnbac1 monoclonal antibody |
- |
- |
- |
- |
1件: 13 |
639 |
Gold |
Gold |
- |
- |
- |
5件: 2, 6, 13, 46, 171 |
640 |
Gold nanocrystals |
Gold |
- |
- |
- |
3件: 2, 6, 13 |
641 |
Granulocyte-colony stimulating factor (g-csf) and prednisone |
Prednisone |
D00473 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 13 |
642 |
Growth hormone |
Somatotropin |
D02691 |
1件: GHR |
5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
11件: 2, 13, 19, 46, 78, 96, 191, 193, 195, 265, 299 |
643 |
Gsk1223249 |
- |
- |
- |
- |
2件: 2, 13 |
644 |
Gsk1841157 |
- |
- |
- |
- |
3件: 13, 35, 46 |
645 |
Gsk2018682 |
Gsk2018682 |
- |
- |
- |
1件: 13 |
646 |
Gsk2018682 cd2 capsule |
Gsk2018682 |
- |
- |
- |
1件: 13 |
647 |
Gsk239512 |
Gsk239512 |
- |
- |
- |
1件: 13 |
648 |
Gsk2395612 |
- |
- |
- |
- |
1件: 13 |
649 |
Gtr.ace |
- |
- |
- |
- |
1件: 13 |
650 |
Guanabenz |
Guanabenz |
D04375 |
3件: ADRA2A, ADRA2B, ADRA2C |
2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
2件: 2, 13 |
651 |
Gw-1000-02 |
- |
- |
- |
- |
1件: 13 |
652 |
Gz402668 |
- |
- |
- |
- |
1件: 13 |
653 |
Gz402673 |
- |
- |
- |
- |
1件: 13 |
654 |
H.p. acthar gel (repository corticotropin injection) |
Corticotropin |
D00146 |
1件: MC2R |
5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
1件: 13 |
655 |
H.p. acthar® gel (repository corticotropin injection) |
Corticotropin |
D00146 |
1件: MC2R |
5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
1件: 13 |
656 |
Helminth ova |
- |
- |
- |
- |
1件: 13 |
657 |
Hematopoetic stem cell infusion |
- |
- |
- |
- |
1件: 13 |
658 |
Hematopoietic stem cell transplantation |
- |
- |
- |
- |
12件: 11, 13, 14, 19, 20, 35, 46, 49, 51, 96, 234, 285 |
659 |
High dose aspirin (1300 mg/day) |
Acetylsalicylic acid |
D00109 |
2件: PTGS1, PTGS2 |
21件: Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
1件: 13 |
660 |
High/low sodium diet |
- |
- |
- |
- |
1件: 13 |
661 |
Histidine |
Histidine |
D00032 |
- |
- |
3件: 13, 169, 170 |
662 |
Hmr 1726d |
- |
- |
- |
- |
1件: 13 |
663 |
Hmr1726 |
- |
- |
- |
- |
1件: 13 |
664 |
Hmr1726d |
- |
- |
- |
- |
1件: 13 |
665 |
Hookworm larvae |
- |
- |
- |
- |
1件: 13 |
666 |
Hp184 |
- |
- |
- |
- |
1件: 13 |
667 |
Human anti-il-12 igg1 mab |
- |
- |
- |
- |
1件: 13 |
668 |
Human anti-il-12 mab |
- |
- |
- |
- |
1件: 13 |
669 |
Human anti-lingo-1 monoclonal antibody |
- |
- |
- |
- |
1件: 13 |
670 |
Human autologous mesenchymal stem cells |
- |
- |
- |
- |
2件: 2, 13 |
671 |
Human fetal-derived neural stem cells (hnscs) |
- |
- |
- |
- |
1件: 13 |
672 |
Human interferon beta |
Human interferon beta |
- |
- |
- |
2件: 13, 26 |
673 |
Human interferon beta 1a (rebif) |
Human interferon beta |
- |
- |
- |
1件: 13 |
674 |
Human interferon beta-1a and glatiramer acetate |
Human interferon beta |
- |
- |
- |
1件: 13 |
675 |
Human leucocyte interferon-alpha |
- |
- |
- |
- |
1件: 13 |
676 |
Human monoclonal antibody (cnto 1275) to interleukin-12p40 |
Ustekinumab |
D09214 |
3件: IL12A, IL12B, IL23A |
25件: African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease (IBD), Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus |
1件: 13 |
677 |
Human neural stem cells |
- |
- |
- |
- |
2件: 2, 13 |
678 |
Human normal immunoglobulin |
Immune globulin human |
- |
- |
- |
8件: 11, 13, 14, 43, 45, 50, 63, 65 |
679 |
Human recombinant growth hormone |
Somatotropin |
D02691 |
1件: GHR |
5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
2件: 13, 299 |
680 |
Human umbilical cord mesenchymal stem cells |
- |
- |
- |
- |
2件: 13, 113 |
681 |
Humax-cd20 |
Ofatumumab |
D09314 |
1件: MS4A1 |
1件: Hematopoietic cell lineage |
2件: 13, 46 |
682 |
Hydrochlorothiazide |
Hydrochlorothiazide |
D00340 |
- |
- |
3件: 13, 67, 225 |
683 |
Hydroxychloroquine |
Hydroxychloroquine |
D08050 |
- |
- |
18件: 13, 41, 46, 48, 49, 53, 56, 66, 84, 89, 90, 96, 222, 234, 254, 271, 298, 299 |
684 |
Hydroxytyrosol |
Hydroxytyrosol |
- |
- |
- |
1件: 13 |
685 |
Hydroxyurea |
Hydroxyurea |
D00341 |
1件: RRM2 |
6件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism, p53 signaling pathway |
8件: 3, 13, 19, 20, 65, 85, 86, 284 |
686 |
Ibudilast |
Ibudilast |
D01385 |
8件: CYSLTR1, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PTGIR |
16件: Apelin signaling pathway, Calcium signaling pathway, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action, Platelet activation, Progesterone-mediated oocyte maturation, Purine metabolism, Regulation of lipolysis in adipocytes, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
2件: 2, 13 |
687 |
Ibuprofen |
Ibuprofen |
D00126, D01122, D04490, D06606 |
2件: PTGS1, PTGS2 |
21件: Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
6件: 13, 46, 65, 113, 271, 299 |
688 |
Idebenone |
Idebenone |
D01750 |
- |
- |
4件: 6, 13, 113, 302 |
689 |
Ifa incomplete freund's adjuvant |
- |
- |
- |
- |
1件: 13 |
690 |
Ifn beta 1 a + curcumin (bcm 95) |
Curcumin |
- |
- |
- |
1件: 13 |
691 |
Ifn beta-1a |
- |
- |
- |
- |
1件: 13 |
692 |
Ifn-beta-1a (rebif®) |
- |
- |
- |
- |
1件: 13 |
693 |
Ifn-beta-1a, (avonex®) |
- |
- |
- |
- |
1件: 13 |
694 |
Ifn-ß-1a (rebif®) |
- |
- |
- |
- |
1件: 13 |
695 |
Ifn-ß-1a, (avonex®) |
- |
- |
- |
- |
1件: 13 |
696 |
Il2 |
Human interleukin-2 |
- |
- |
- |
1件: 13 |
697 |
Imatinib |
Imatinib |
D01441, D08066 |
3件: ABL1, KIT, PDGFRA |
32件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Shigellosis, Viral myocarditis |
11件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
698 |
Imatinib mesilate |
Imatinib |
D01441, D08066 |
3件: ABL1, KIT, PDGFRA |
32件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Shigellosis, Viral myocarditis |
2件: 13, 86 |
699 |
Imatinib mesylate |
Imatinib |
D01441, D08066 |
3件: ABL1, KIT, PDGFRA |
32件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Shigellosis, Viral myocarditis |
5件: 13, 28, 34, 51, 86 |
700 |
Immune globulin |
- |
- |
- |
- |
3件: 11, 13, 14 |
701 |
Immune globulin iv [human], 10% caprylate/chromatography purified |
- |
- |
- |
- |
1件: 13 |
702 |
Immunoglobulin |
- |
- |
- |
- |
2件: 13, 14 |
703 |
Immunoglobulin g |
Immune globulin human |
- |
- |
- |
7件: 11, 13, 14, 49, 50, 63, 65 |
704 |
Impact |
Topramezone |
- |
- |
- |
7件: 6, 13, 46, 50, 96, 97, 299 |
705 |
Imu-838 (30 mg/day) |
- |
- |
- |
- |
1件: 13 |
706 |
Imu-838 (45 mg/day) |
- |
- |
- |
- |
1件: 13 |
707 |
Incabotulinumtoxina |
- |
- |
- |
- |
1件: 13 |
708 |
Inf beta-1a |
- |
- |
- |
- |
1件: 13 |
709 |
Influenza vaccine |
- |
- |
- |
- |
4件: 11, 13, 46, 84 |
710 |
Inhaled cannabis |
Medical cannabis |
- |
- |
- |
1件: 13 |
711 |
Injectable ms dmt |
- |
- |
- |
- |
1件: 13 |
712 |
Injection of autologous stem cells |
- |
- |
- |
- |
1件: 13 |
713 |
Injection of cell free media |
- |
- |
- |
- |
1件: 13 |
714 |
Inn colecalciferol |
Cholecalciferol |
D00188 |
1件: VDR |
4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
1件: 13 |
715 |
Inosine |
Inosine |
D00054 |
- |
- |
4件: 2, 6, 13, 17 |
716 |
Insulin |
- |
- |
- |
- |
5件: 13, 46, 75, 78, 299 |
717 |
Int131 |
- |
- |
- |
- |
1件: 13 |
718 |
Interferon beta |
Human interferon beta |
- |
- |
- |
6件: 13, 14, 20, 26, 96, 97 |
719 |
Interferon beta - 1a (ifn) |
Human interferon beta |
- |
- |
- |
1件: 13 |
720 |
Interferon beta -1b |
Human interferon beta |
- |
- |
- |
1件: 13 |
721 |
Interferon beta 1 |
Human interferon beta |
- |
- |
- |
1件: 13 |
722 |
Interferon beta 1-a |
Interferon beta-1a |
D04554 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
723 |
Interferon beta 1-b (betaferon/betaseron, bay86-5046) |
Human interferon beta |
- |
- |
- |
1件: 13 |
724 |
Interferon beta 1a |
Interferon beta-1a |
D04554 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
725 |
Interferon beta 1a 30 ug im once weekly |
Interferon beta-1a |
D04554 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
726 |
Interferon beta 1a, oral doxycycline |
Doxycycline |
D00307, D02129, D03903, D03904, D07876 |
- |
- |
1件: 13 |
727 |
Interferon beta 1b |
Interferon beta-1b |
D00746 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
728 |
Interferon beta 1b (betaseron, bay86-5046) |
Interferon beta-1b |
D00746 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
729 |
Interferon beta treatment to add-on atorvastatin treatment |
Atorvastatin |
D00258, D00887, D07474 |
1件: HMGCR |
4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
1件: 13 |
730 |
Interferon beta type 1a |
Human interferon beta |
- |
- |
- |
1件: 13 |
731 |
Interferon beta-1 a |
Human interferon beta |
- |
- |
- |
1件: 13 |
732 |
Interferon beta-1a |
Human interferon beta |
- |
- |
- |
5件: 13, 14, 26, 96, 97 |
733 |
Interferon beta-1a (avonex) |
Human interferon beta |
- |
- |
- |
1件: 13 |
734 |
Interferon beta-1a (avonex®) |
Human interferon beta |
- |
- |
- |
1件: 13 |
735 |
Interferon beta-1a (current approved manufacturing process invloving fbs) |
Human interferon beta |
- |
- |
- |
1件: 13 |
736 |
Interferon beta-1a (new process, manufactured without fbs) |
Human interferon beta |
- |
- |
- |
1件: 13 |
737 |
Interferon beta-1a (rebif) |
Human interferon beta |
- |
- |
- |
1件: 13 |
738 |
Interferon beta-1a 30 µg |
Human interferon beta |
- |
- |
- |
1件: 13 |
739 |
Interferon beta-1a fbs-free/hsa-free, rnf |
Human interferon beta |
- |
- |
- |
1件: 13 |
740 |
Interferon beta-1a hsa+ biosimilar |
Human interferon beta |
- |
- |
- |
1件: 13 |
741 |
Interferon beta-1a hsa-free biosimilar |
Human interferon beta |
- |
- |
- |
1件: 13 |
742 |
Interferon beta-1a original |
Human interferon beta |
- |
- |
- |
1件: 13 |
743 |
Interferon beta-1b |
Human interferon beta |
- |
- |
- |
1件: 13 |
744 |
Interferon beta-1b (betaferon, bay 86-5046) |
Human interferon beta |
- |
- |
- |
1件: 13 |
745 |
Interferon beta-1b (betaferon, bay86-5046) |
Human interferon beta |
- |
- |
- |
1件: 13 |
746 |
Interferon beta-1b (betaferon/betaseron, bay86-5046) |
Human interferon beta |
- |
- |
- |
1件: 13 |
747 |
Interferon beta-1b (betaferon®, bay 86-5046) |
Human interferon beta |
- |
- |
- |
1件: 13 |
748 |
Interferon beta-1b (betaseron, bay86-5046) |
Human interferon beta |
- |
- |
- |
1件: 13 |
749 |
Interferon beta-1b (betaseron, betaferon, bay86-5046) |
Human interferon beta |
- |
- |
- |
1件: 13 |
750 |
Interferon beta-1b (pf530, betaferon) |
Human interferon beta |
- |
- |
- |
1件: 13 |
751 |
Interferon beta-1b and tacrolimus |
Tacrolimus |
D00107, D08556 |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
30件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
1件: 13 |
752 |
Interferon beta-1b group |
Human interferon beta |
- |
- |
- |
1件: 13 |
753 |
Interferon beta-1b, (betaseron bay86-5046) |
Human interferon beta |
- |
- |
- |
1件: 13 |
754 |
Interferon beta-1b/atorvastatin group |
Atorvastatin |
D00258, D00887, D07474 |
1件: HMGCR |
4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
1件: 13 |
755 |
Interferon beta1a |
Interferon beta1a |
D04554 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
756 |
Interferon ß-1a |
- |
- |
- |
- |
1件: 13 |
757 |
Interferon ß-1a (avonex®) |
Interferon beta-1a |
D04554 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
758 |
Interferon ß-1a 30 µg |
- |
- |
- |
- |
1件: 13 |
759 |
Interferon ß-1b |
- |
- |
- |
- |
1件: 13 |
760 |
Interferon-1beta (betaseron, bay86-5046) |
- |
- |
- |
- |
1件: 13 |
761 |
Interferon-beta |
Human interferon beta |
- |
- |
- |
2件: 13, 97 |
762 |
Interferon-beta (ifn-beta) |
Human interferon beta |
- |
- |
- |
1件: 13 |
763 |
Interferon-beta 1a |
Human interferon beta |
- |
- |
- |
1件: 13 |
764 |
Interferon-beta 1a fbs-free/hsa free, rnf |
Human interferon beta |
- |
- |
- |
1件: 13 |
765 |
Interferon-beta 1a fbs-free/hsa-free, rnf |
Human interferon beta |
- |
- |
- |
1件: 13 |
766 |
Interferon-beta 1b |
Human interferon beta |
- |
- |
- |
1件: 13 |
767 |
Interferon-beta 1b (betaseron) |
Human interferon beta |
- |
- |
- |
1件: 13 |
768 |
Interferon-beta-1a |
Interferon beta-1a |
D04554 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
2件: 13, 97 |
769 |
Interferon-beta-1a fbs-free/hsa free, rnf |
Interferon beta-1a |
D04554 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
770 |
Interferon-beta-1a fbs-free/hsa-free |
Interferon beta-1a |
D04554 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
771 |
Interferon-beta-1b |
Interferon beta-1b |
D00746 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
772 |
Interferon-beta1 |
Human interferon beta |
- |
- |
- |
1件: 13 |
773 |
Interferon-ß-1a |
- |
- |
- |
- |
1件: 13 |
774 |
Interferon-ß-1b |
- |
- |
- |
- |
1件: 13 |
775 |
Intradetrusor injection of botulinum toxin-a |
- |
- |
- |
- |
1件: 13 |
776 |
Intratect |
- |
- |
- |
- |
3件: 13, 35, 65 |
777 |
Intrathecal administration of autologous msc-np |
- |
- |
- |
- |
1件: 13 |
778 |
Intrathecal methotrexate |
Methotrexate |
D00142, D02115 |
2件: DHFR, DHFR2 |
4件: Antifolate resistance, Folate biosynthesis, Metabolic pathways, One carbon pool by folate |
1件: 13 |
779 |
Intrathecal msc-np injection |
- |
- |
- |
- |
1件: 13 |
780 |
Intravenous (iv) infusions |
- |
- |
- |
- |
1件: 13 |
781 |
Intravenous injection of mesenchymal stem cells |
- |
- |
- |
- |
1件: 13 |
782 |
Intravenous steroid |
- |
- |
- |
- |
1件: 13 |
783 |
Ipx056 |
- |
- |
- |
- |
1件: 13 |
784 |
Ipx056-10 mg |
- |
- |
- |
- |
1件: 13 |
785 |
Ipx056-20 mg |
- |
- |
- |
- |
1件: 13 |
786 |
Ipx056-30 mg |
- |
- |
- |
- |
1件: 13 |
787 |
Ipx056-35 mg |
- |
- |
- |
- |
1件: 13 |
788 |
Ipx056-40 mg |
- |
- |
- |
- |
1件: 13 |
789 |
Ir902 |
- |
- |
- |
- |
1件: 13 |
790 |
Iron |
Iron |
- |
- |
- |
7件: 13, 62, 86, 96, 97, 254, 284 |
791 |
Iron oxide |
Iron |
- |
- |
- |
1件: 13 |
792 |
Isentress |
Raltegravir |
D06676 |
- |
- |
1件: 13 |
793 |
Isoxsuprine |
Isoxsuprine |
D08092 |
1件: ADRB2 |
8件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 13 |
794 |
Isoxsuprine hydrochloride |
Isoxsuprine |
D08092 |
1件: ADRB2 |
8件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 13 |
795 |
Iv methylprednisolone |
Methylprednisolone |
D00407, D00751, D00979, D05000, D05001, D05002 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 13 |
796 |
Iv methylprednisolone (steroids) |
Methylprednisolone |
D00407, D00751, D00979, D05000, D05001, D05002 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 13 |
797 |
Ivig |
Immune globulin human |
- |
- |
- |
12件: 11, 13, 14, 17, 18, 50, 51, 63, 65, 85, 164, 296 |
798 |
Ixazomib |
Ixazomib |
D10130 |
1件: PSMB5 |
1件: Proteasome |
3件: 13, 16, 28 |
799 |
Ixazomib (ninlaro®) capsules |
Ixazomib |
D10130 |
1件: PSMB5 |
1件: Proteasome |
1件: 13 |
800 |
Jm-4 |
- |
- |
- |
- |
1件: 13 |
801 |
Kemstro |
Baclofen |
D00241 |
2件: GABBR1, GABBR2 |
7件: Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway |
1件: 13 |
802 |
Kepivance |
Palifermin |
D05338 |
1件: FGFR2 |
12件: Central carbon metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Gastric cancer, MAPK signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Signaling pathways regulating pluripotency of stem cells |
1件: 13 |
803 |
Keppra |
Levetiracetam |
D00709 |
1件: SV2A |
1件: ECM-receptor interaction |
1件: 13 |
804 |
Keppra 250mg |
Levetiracetam |
D00709 |
1件: SV2A |
1件: ECM-receptor interaction |
1件: 13 |
805 |
Keppra 500mg |
Levetiracetam |
D00709 |
1件: SV2A |
1件: ECM-receptor interaction |
1件: 13 |
806 |
Keppra ® |
Levetiracetam |
D00709 |
1件: SV2A |
1件: ECM-receptor interaction |
1件: 13 |
807 |
Ketamine |
Ketamine |
D00711, D08098 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
5件: 13, 70, 113, 156, 215 |
808 |
Ketoconazole |
Ketoconazole |
D00351 |
1件: CYP17A1 |
6件: Cortisol synthesis and secretion, Cushing syndrome, Metabolic pathways, Ovarian steroidogenesis, Prolactin signaling pathway, Steroid hormone biosynthesis |
3件: 8, 13, 75 |
809 |
Keyhole limpet hemocyanin |
Keyhole limpet hemocyanin |
- |
- |
- |
2件: 13, 46 |
810 |
Keyhole limpet hemocyanin (klh) |
Keyhole limpet hemocyanin |
- |
- |
- |
1件: 13 |
811 |
Keyhole limpet hemocyanin (klh) neo-antigen |
Keyhole limpet hemocyanin |
- |
- |
- |
1件: 13 |
812 |
L acetyl carnitine |
Levocarnitine |
D02030, D02176, D04713 |
- |
- |
1件: 13 |
813 |
L-000124467 |
- |
- |
- |
- |
2件: 13, 46 |
814 |
L-carnitine |
Levocarnitine |
D02030, D02176, D04713 |
- |
- |
6件: 13, 96, 97, 265, 298, 316 |
815 |
L-histidine |
Histidine |
D00032 |
- |
- |
1件: 13 |
816 |
L04aa04 - immunoglobulina antitimocitaria (di coniglio) immunoglobulina di coniglio antitimociti umani thymoglobuline |
- |
- |
- |
- |
1件: 13 |
817 |
L04aa31 |
- |
- |
- |
- |
1件: 13 |
818 |
L04ax01 |
- |
- |
- |
- |
1件: 13 |
819 |
Lactose |
Lactose |
D00046, D03226 |
- |
- |
6件: 2, 6, 13, 97, 228, 310 |
820 |
Lactose monohydrate |
Lactose |
D00046, D03226 |
- |
- |
1件: 13 |
821 |
Lamotrigine |
Lamotrigine |
D00354 |
5件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A |
3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
3件: 13, 34, 114 |
822 |
Lamotrigine extended release tablets |
Lamotrigine |
D00354 |
5件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A |
3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
1件: 13 |
823 |
Laquinimod |
Laquinimod |
- |
- |
- |
4件: 8, 13, 49, 96 |
824 |
Laquinimod 0.6 |
Laquinimod |
- |
- |
- |
1件: 13 |
825 |
Laquinimod 1.2 |
Laquinimod |
- |
- |
- |
1件: 13 |
826 |
Laquinimod capsules 0.3 mg |
Laquinimod |
- |
- |
- |
1件: 13 |
827 |
Laquinimod capsules 0.6 mg |
Laquinimod |
- |
- |
- |
1件: 13 |
828 |
Laquinimod sodium (usan) |
Laquinimod |
- |
- |
- |
1件: 13 |
829 |
Laquinimod tablets 0.3 mg |
Laquinimod |
- |
- |
- |
1件: 13 |
830 |
Lemtrada |
Alemtuzumab |
D02802 |
- |
- |
2件: 13, 65 |
831 |
Lemtrada 12 mg konzentrat zur herstellung einer infusionslösung |
Alemtuzumab |
D02802 |
- |
- |
1件: 13 |
832 |
Levetiracetam |
Levetiracetam |
D00709 |
1件: SV2A |
1件: ECM-receptor interaction |
4件: 2, 4, 6, 13 |
833 |
Levitra |
Vardenafil |
D02731, D03260, D08668 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
2件: 13, 86 |
834 |
Levocarnil |
- |
- |
- |
- |
1件: 13 |
835 |
Levofolene |
Levoleucovorin |
D04715 |
- |
- |
1件: 13 |
836 |
Levofolene 4 mg 30 cpr |
Levoleucovorin |
D04715 |
- |
- |
1件: 13 |
837 |
Levonorgestrel |
Levonorgestrel |
D00950 |
1件: PGR |
4件: Breast cancer, Estrogen signaling pathway, Oocyte meiosis, Progesterone-mediated oocyte maturation |
1件: 13 |
838 |
Lfb-r603 |
- |
- |
- |
- |
1件: 13 |
839 |
Lidocaine |
Lidocaine |
D00358, D02086, D08127 |
5件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A |
3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
8件: 6, 13, 46, 86, 168, 226, 231, 256 |
840 |
Lidocaine patch 5% |
Lidocaine |
D00358, D02086, D08127 |
5件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A |
3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
1件: 13 |
841 |
Linoleic acid |
Linoleic acid |
- |
- |
- |
1件: 13 |
842 |
Linoleic acid/oleic acid |
Linoleic acid |
- |
- |
- |
1件: 13 |
843 |
Liothyronine |
Liothyronine |
D01011, D08128 |
2件: THRA, THRB |
2件: Neuroactive ligand-receptor interaction, Thyroid hormone signaling pathway |
2件: 13, 212 |
844 |
Liothyronine sodium |
Liothyronine |
D01011, D08128 |
2件: THRA, THRB |
2件: Neuroactive ligand-receptor interaction, Thyroid hormone signaling pathway |
1件: 13 |
845 |
Lipoic acid |
Lipoic acid |
D00048, D00086 |
- |
- |
5件: 2, 5, 13, 14, 20 |
846 |
Lipoic acid (la) with fish oil and la without fish oil |
Lipoic acid |
D00048, D00086 |
- |
- |
1件: 13 |
847 |
Lipoic acid and omega-3 fatty acids |
Lipoic acid |
D00048, D00086 |
- |
- |
1件: 13 |
848 |
Lisdexamfetamine |
Lisdexamfetamine |
D08130 |
2件: SLC6A2, SLC6A3 |
6件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Synaptic vesicle cycle |
1件: 13 |
849 |
Lisdexamfetamine sulfate |
Lisdexamfetamine |
D08130 |
2件: SLC6A2, SLC6A3 |
6件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Synaptic vesicle cycle |
1件: 13 |
850 |
Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field |
- |
- |
- |
- |
1件: 13 |
851 |
Lithium carbonate |
Lithium carbonate |
D00801 |
- |
- |
5件: 2, 13, 17, 19, 127 |
852 |
Live hookworm larvae |
- |
- |
- |
- |
1件: 13 |
853 |
Live necator americanus larvae |
- |
- |
- |
- |
1件: 13 |
854 |
Loperamide |
Loperamide |
D00729, D07113, D08144 |
3件: OPRD1, OPRK1, OPRM1 |
5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
2件: 13, 97 |
855 |
Loratadine |
Loratadine |
D00364 |
1件: HRH1 |
3件: Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction |
2件: 13, 46 |
856 |
Losartan |
Losartan |
D00357, D08146 |
1件: AGTR1 |
14件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
18件: 13, 17, 19, 46, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299 |
857 |
Low dose arm receiving neutral oil and 400 iu/g of vitamin d every second day |
Vitamin d |
- |
- |
- |
1件: 13 |
858 |
Low dose aspirin (162 mg/day) |
Acetylsalicylic acid |
D00109 |
2件: PTGS1, PTGS2 |
21件: Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
1件: 13 |
859 |
Low immunogenic interferon-beta-1a |
Interferon beta-1a |
D04554 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
860 |
Lubiprostone |
Lubiprostone |
D04790 |
1件: CLCN2 |
1件: Mineral absorption |
4件: 6, 13, 290, 299 |
861 |
Lumbar puncture |
- |
- |
- |
- |
3件: 13, 96, 97 |
862 |
Lutenyl |
- |
- |
- |
- |
1件: 13 |
863 |
Ly2127399 |
- |
- |
- |
- |
3件: 13, 46, 49 |
864 |
Ly248686 |
Duloxetine |
D01179, D07880 |
2件: SLC6A2, SLC6A4 |
2件: Serotonergic synapse, Synaptic vesicle cycle |
1件: 13 |
865 |
Lysine |
L-lysine |
D02304 |
- |
- |
4件: 13, 97, 228, 299 |
866 |
M2951 |
- |
- |
- |
- |
3件: 13, 46, 49 |
867 |
Mabcampath |
Alemtuzumab |
D02802 |
- |
- |
1件: 13 |
868 |
Mabcampath ® |
Alemtuzumab |
D02802 |
- |
- |
1件: 13 |
869 |
Mabthera |
- |
- |
- |
- |
15件: 11, 13, 35, 46, 50, 51, 53, 61, 63, 64, 65, 83, 162, 222, 271 |
870 |
Mabthera (rituximab) |
Rituximab |
D02994 |
1件: MS4A1 |
1件: Hematopoietic cell lineage |
4件: 13, 46, 49, 53 |
871 |
Mabthera or biosimilar rituximab product |
Rituximab |
D02994 |
1件: MS4A1 |
1件: Hematopoietic cell lineage |
1件: 13 |
872 |
Mabthera® |
- |
- |
- |
- |
6件: 13, 35, 43, 44, 46, 93 |
873 |
Magnesium |
Magnesium |
- |
- |
- |
15件: 6, 11, 13, 46, 64, 93, 97, 166, 225, 235, 284, 291, 296, 297, 298 |
874 |
Maltodextrin |
Maltodextrin |
D02329 |
- |
- |
4件: 6, 13, 96, 97 |
875 |
Maltodextrin fiber supplement |
Maltodextrin |
D02329 |
- |
- |
1件: 13 |
876 |
Mangafodipir |
Mangafodipir |
D08262 |
- |
- |
2件: 13, 58 |
877 |
Mangafodipir (teslascan) |
Mangafodipir |
D08262 |
- |
- |
1件: 13 |
878 |
Mannose |
Mannose |
- |
- |
- |
2件: 13, 256 |
879 |
Mantadan*20cpr 100mg |
- |
- |
- |
- |
1件: 13 |
880 |
Marijuana |
Medical cannabis |
- |
- |
- |
1件: 13 |
881 |
Masitinb mesylate |
- |
- |
- |
- |
1件: 13 |
882 |
Masitinib |
Masitinib |
D10229 |
1件: KIT |
11件: Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer, Hematopoietic cell lineage, MAPK signaling pathway, Melanogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway |
6件: 2, 5, 6, 13, 46, 96 |
883 |
Masitinib mesylate |
Masitinib |
D10229 |
1件: KIT |
11件: Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer, Hematopoietic cell lineage, MAPK signaling pathway, Melanogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway |
6件: 2, 5, 6, 13, 46, 96 |
884 |
Mastinib |
- |
- |
- |
- |
1件: 13 |
885 |
Mavenclad® |
- |
- |
- |
- |
1件: 13 |
886 |
Mbp peptide |
- |
- |
- |
- |
1件: 13 |
887 |
Mbp8298 |
- |
- |
- |
- |
1件: 13 |
888 |
Mbp8298 synthetic peptide |
- |
- |
- |
- |
1件: 13 |
889 |
Md1003 |
- |
- |
- |
- |
5件: 2, 10, 13, 14, 20 |
890 |
Md1003 100mg capsule |
- |
- |
- |
- |
1件: 13 |
891 |
Medi-551 |
- |
- |
- |
- |
1件: 13 |
892 |
Medi-551 iv |
- |
- |
- |
- |
1件: 13 |
893 |
Medi-551 sc |
- |
- |
- |
- |
1件: 13 |
894 |
Medical marijuana |
Medical cannabis |
- |
- |
- |
1件: 13 |
895 |
Medrol |
Methylprednisolone |
D00407, D00751, D00979, D05000, D05001, D05002 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
2件: 13, 222 |
896 |
Megadose oral methylprednisolone |
Methylprednisolone |
D00407, D00751, D00979, D05000, D05001, D05002 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 13 |
897 |
Melatonin |
Melatonin |
D08170 |
2件: MTNR1A, MTNR1B |
2件: Circadian entrainment, Neuroactive ligand-receptor interaction |
8件: 6, 13, 46, 49, 90, 97, 144, 202 |
898 |
Melphalan |
Melphalan |
D00369 |
- |
- |
14件: 11, 13, 14, 19, 20, 28, 60, 62, 65, 96, 164, 234, 284, 285 |
899 |
Memantine |
Memantine |
D04905, D08174 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
7件: 2, 6, 8, 13, 49, 127, 205 |
900 |
Meningococcal polysaccharide diphtheria conjugate vaccine (quadrivalent) |
- |
- |
- |
- |
1件: 13 |
901 |
Menitorix |
- |
- |
- |
- |
1件: 13 |
902 |
Mesenchymal stem cells |
- |
- |
- |
- |
11件: 2, 6, 13, 20, 49, 51, 60, 96, 222, 274, 299 |
903 |
Mesenchymal stem cells (mscs) |
- |
- |
- |
- |
3件: 13, 36, 96 |
904 |
Mesenchymal stem/stromal cells |
- |
- |
- |
- |
1件: 13 |
905 |
Mesna |
Coenzyme m |
- |
- |
- |
9件: 13, 44, 45, 49, 51, 60, 65, 96, 164 |
906 |
Metex |
- |
- |
- |
- |
1件: 13 |
907 |
Metformin |
Metformin |
D00944, D04966 |
2件: PRKAA1, PRKAA2 |
19件: AMPK signaling pathway, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy (HCM), Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease (NAFLD), Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway |
16件: 6, 13, 46, 49, 67, 75, 77, 81, 86, 113, 158, 206, 225, 233, 265, 285 |
908 |
Methelphenidate |
- |
- |
- |
- |
1件: 13 |
909 |
Methotrexat |
Methotrexate |
D00142, D02115 |
2件: DHFR, DHFR2 |
4件: Antifolate resistance, Folate biosynthesis, Metabolic pathways, One carbon pool by folate |
3件: 13, 46, 50 |
910 |
Methotrexate |
Methotrexate |
D00142, D02115 |
2件: DHFR, DHFR2 |
4件: Antifolate resistance, Folate biosynthesis, Metabolic pathways, One carbon pool by folate |
33件: 11, 13, 19, 34, 35, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 162, 164, 172, 256, 271, 284, 285, 326, 331 |
911 |
Methyl b12 |
- |
- |
- |
- |
1件: 13 |
912 |
Methyl folate |
Folic acid |
D00070 |
- |
- |
1件: 13 |
913 |
Methyloprednisolone |
- |
- |
- |
- |
1件: 13 |
914 |
Methylphenidate |
Methylphenidate |
D01296, D04999 |
2件: SLC6A2, SLC6A3 |
6件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Synaptic vesicle cycle |
7件: 6, 13, 34, 84, 113, 179, 206 |
915 |
Methylphenidate hydrochloride |
Methylphenidate |
D01296, D04999 |
2件: SLC6A2, SLC6A3 |
6件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Synaptic vesicle cycle |
2件: 6, 13 |
916 |
Methylphenidate modified release |
Methylphenidate |
D01296, D04999 |
2件: SLC6A2, SLC6A3 |
6件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Synaptic vesicle cycle |
1件: 13 |
917 |
Methylphenidate modified release 20 mg |
Methylphenidate |
D01296, D04999 |
2件: SLC6A2, SLC6A3 |
6件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Synaptic vesicle cycle |
1件: 13 |
918 |
Methylphenidate modified release 30 mg |
Methylphenidate |
D01296, D04999 |
2件: SLC6A2, SLC6A3 |
6件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Synaptic vesicle cycle |
1件: 13 |
919 |
Methylphenidate modified release 40 mg |
Methylphenidate |
D01296, D04999 |
2件: SLC6A2, SLC6A3 |
6件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Synaptic vesicle cycle |
1件: 13 |
920 |
Methylprednisolon |
Methylprednisolone |
D00407, D00751, D00979, D05000, D05001, D05002 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
4件: 13, 51, 66, 222 |
921 |
Methylprednisolon-21-hydrogensuccinat, natriumsalz |
Methylprednisolone |
D00407, D00751, D00979, D05000, D05001, D05002 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 13 |
922 |
Methylprednisolone |
Methylprednisolone |
D00407, D00751, D00979, D05000, D05001, D05002 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
36件: 2, 13, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 63, 64, 65, 66, 83, 84, 86, 96, 97, 145, 164, 220, 222, 224, 271, 283, 284, 285, 296 |
923 |
Methylprednisolone (drug) |
Methylprednisolone |
D00407, D00751, D00979, D05000, D05001, D05002 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 13 |
924 |
Methylprednisolone hemisuccinate |
Methylprednisolone hemisuccinate |
D05000 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 13 |
925 |
Methylprednisolone iv |
Methylprednisolone |
D00407, D00751, D00979, D05000, D05001, D05002 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 13 |
926 |
Methylprednisolone sodium hemisuccinate |
Methylprednisolone |
D00407, D00751, D00979, D05000, D05001, D05002 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 13 |
927 |
Methylprednisolone sodium succinate |
Methylprednisolone |
D00407, D00751, D00979, D05000, D05001, D05002 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
3件: 13, 46, 51 |
928 |
Microgynon |
- |
- |
- |
- |
2件: 13, 51 |
929 |
Microgynon® |
- |
- |
- |
- |
1件: 13 |
930 |
Micropirin |
- |
- |
- |
- |
1件: 13 |
931 |
Midazolam |
Midazolam |
D00550, D00696, D05028 |
16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
10件: 2, 3, 6, 13, 46, 70, 96, 97, 231, 298 |
932 |
Mineral boost (magnesium) |
Magnesium |
- |
- |
- |
1件: 13 |
933 |
Minocycline |
Minocycline |
D00850, D05045 |
- |
- |
13件: 2, 6, 8, 13, 46, 85, 90, 94, 162, 201, 206, 280, 299 |
934 |
Minocycline 100 mg film-coated tablets |
Minocycline |
D00850, D05045 |
- |
- |
1件: 13 |
935 |
Minocycline hydrochloride |
Minocycline |
D00850, D05045 |
- |
- |
4件: 13, 201, 206, 299 |
936 |
Mirabegron |
Mirabegron |
D09535 |
1件: ADRB3 |
7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, cGMP-PKG signaling pathway |
3件: 6, 13, 226 |
937 |
Mis416 |
- |
- |
- |
- |
1件: 13 |
938 |
Mitoquinone |
Mitoquinone |
- |
- |
- |
1件: 13 |
939 |
Mitoxantrone |
Mitoxantrone |
D02166, D08224 |
2件: TOP2A, TOP2B |
1件: Platinum drug resistance |
1件: 13 |
940 |
Mk0812 |
Mk0812 |
- |
- |
- |
2件: 13, 46 |
941 |
Mln1202 |
- |
- |
- |
- |
1件: 13 |
942 |
Modafinil |
Modafinil |
D01832 |
- |
- |
4件: 6, 13, 49, 93 |
943 |
Mog peptide |
- |
- |
- |
- |
1件: 13 |
944 |
Monitor |
Methamidophos |
- |
- |
- |
12件: 2, 11, 13, 19, 46, 49, 58, 70, 85, 98, 298, 300 |
945 |
Monoclonal antibody m-t412 |
- |
- |
- |
- |
1件: 13 |
946 |
Montelukast |
Montelukast |
D00529, D08229 |
1件: CYSLTR1 |
2件: Calcium signaling pathway, Neuroactive ligand-receptor interaction |
5件: 13, 46, 85, 98, 228 |
947 |
Mor103 |
- |
- |
- |
- |
2件: 13, 46 |
948 |
Msc2015 |
- |
- |
- |
- |
1件: 13 |
949 |
Msc2304479a |
- |
- |
- |
- |
1件: 13 |
950 |
Msc2304480a |
- |
- |
- |
- |
1件: 13 |
951 |
Msc2304481a |
- |
- |
- |
- |
1件: 13 |
952 |
Msc2304482a |
- |
- |
- |
- |
1件: 13 |
953 |
Msc2358825a |
- |
- |
- |
- |
1件: 13 |
954 |
Msc2430913a or ono-4641 (to be used as synonyms) |
- |
- |
- |
- |
1件: 13 |
955 |
Msc2491529a |
- |
- |
- |
- |
1件: 13 |
956 |
Msdmds other than betaseron (interferon beta-1b, bay86-5046) |
Human interferon beta |
- |
- |
- |
1件: 13 |
957 |
Mstc-001 (ms-stat) |
- |
- |
- |
- |
1件: 13 |
958 |
Mt-1303 |
- |
- |
- |
- |
2件: 13, 96 |
959 |
Mt-1303-forma |
- |
- |
- |
- |
1件: 13 |
960 |
Mt-1303-formb |
- |
- |
- |
- |
1件: 13 |
961 |
Mt-1303-high |
- |
- |
- |
- |
1件: 13 |
962 |
Mt-1303-low |
- |
- |
- |
- |
1件: 13 |
963 |
Mt-1303-middle |
- |
- |
- |
- |
1件: 13 |
964 |
Multiferon |
- |
- |
- |
- |
1件: 13 |
965 |
Multiple (4 autologous subcutaneous t cell vaccinations with t cell lines reactive to nine myelin peptides) |
- |
- |
- |
- |
1件: 13 |
966 |
Mutagrip |
- |
- |
- |
- |
2件: 11, 13 |
967 |
Mycophenolate |
Mycophenolic acid |
D05096 |
2件: IMPDH1, IMPDH2 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
33件: 2, 11, 13, 14, 19, 20, 28, 35, 36, 42, 43, 45, 49, 51, 53, 60, 62, 65, 66, 84, 85, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 |
968 |
Mycophenolate mofetil |
Mycophenolate mofetil |
D00752, D05094, D05095 |
2件: IMPDH1, IMPDH2 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
32件: 2, 11, 13, 14, 19, 20, 28, 35, 36, 42, 43, 45, 49, 51, 53, 60, 62, 65, 66, 85, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 |
969 |
Mycophenolate mofetil (cellcept) |
Mycophenolate mofetil |
D00752, D05094, D05095 |
2件: IMPDH1, IMPDH2 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
2件: 11, 13 |
970 |
N acetylcysteine |
Acetylcysteine |
D00221 |
- |
- |
1件: 13 |
971 |
N-acetyl cysteine |
L-cysteine |
D00026, D02326 |
- |
- |
5件: 13, 19, 85, 88, 296 |
972 |
N-acetylcysteine |
Acetylcysteine |
D00221 |
- |
- |
10件: 6, 13, 19, 20, 49, 58, 85, 111, 164, 299 |
973 |
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine |
- |
- |
- |
- |
1件: 13 |
974 |
N.a. |
- |
- |
- |
- |
8件: 3, 6, 8, 13, 46, 97, 240, 256 |
975 |
N02bg10 |
- |
- |
- |
- |
1件: 13 |
976 |
N03ax12 |
- |
- |
- |
- |
1件: 13 |
977 |
N06dx01 |
- |
- |
- |
- |
1件: 13 |
978 |
Nabilone |
Nabilone |
D05099 |
2件: CNR1, CNR2 |
4件: Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis |
2件: 6, 13 |
979 |
Naltrexone |
Naltrexone |
D02095, D05113 |
3件: OPRD1, OPRK1, OPRM1 |
5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
11件: 6, 10, 13, 40, 41, 42, 43, 44, 45, 96, 97 |
980 |
Namisol |
- |
- |
- |
- |
2件: 13, 298 |
981 |
Nanocort |
- |
- |
- |
- |
3件: 13, 46, 97 |
982 |
Nanocurcumin |
- |
- |
- |
- |
2件: 13, 271 |
983 |
Naproxen |
Naproxen |
D00118 |
2件: PTGS1, PTGS2 |
21件: Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
3件: 13, 46, 271 |
984 |
Natalizumab |
Natalizumab |
D06886 |
1件: ITGA4 |
14件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection |
4件: 13, 15, 46, 96 |
985 |
Natalizumab (bg00002) |
Natalizumab |
D06886 |
1件: ITGA4 |
14件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection |
1件: 13 |
986 |
Natalizumab (ntz) |
Natalizumab |
D06886 |
1件: ITGA4 |
14件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection |
1件: 13 |
987 |
Natalizumab (tysabri) |
Natalizumab |
D06886 |
1件: ITGA4 |
14件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection |
1件: 13 |
988 |
Natalizumab for iv infusion |
Natalizumab |
D06886 |
1件: ITGA4 |
14件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection |
1件: 13 |
989 |
Natalizumab for subcutaneous injection |
Natalizumab |
D06886 |
1件: ITGA4 |
14件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection |
1件: 13 |
990 |
Natalizumab treatment |
Natalizumab |
D06886 |
1件: ITGA4 |
14件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection |
1件: 13 |
991 |
Nbi-5788 |
- |
- |
- |
- |
1件: 13 |
992 |
Nebido® testosterone undecanoate 1000 mg/4 ml solution for injection |
Testosterone undecanoate |
D06087 |
1件: AR |
3件: Oocyte meiosis, Pathways in cancer, Prostate cancer |
1件: 13 |
993 |
Necator americanus |
- |
- |
- |
- |
1件: 13 |
994 |
Neorecormon |
- |
- |
- |
- |
1件: 13 |
995 |
Nerispirdine |
Nerispirdine |
- |
- |
- |
1件: 13 |
996 |
Nerispirdine (hp184) |
Nerispirdine |
- |
- |
- |
1件: 13 |
997 |
Nerispirdine hydrochloride |
Nerispirdine |
- |
- |
- |
1件: 13 |
998 |
Neupogen |
Filgrastim |
D03235 |
1件: CSF3R |
5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
4件: 13, 28, 51, 285 |
999 |
Neuroaspis plp10® |
- |
- |
- |
- |
1件: 13 |
1000 |
Neurontin |
Gabapentin |
D00332 |
5件: CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, SLC6A1 |
9件: Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cardiac muscle contraction, Dilated cardiomyopathy (DCM), GABAergic synapse, Hypertrophic cardiomyopathy (HCM), MAPK signaling pathway, Oxytocin signaling pathway, Synaptic vesicle cycle |
1件: 13 |
1001 |
Neurontin 300 mg hard capsule |
Gabapentin |
D00332 |
5件: CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, SLC6A1 |
9件: Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cardiac muscle contraction, Dilated cardiomyopathy (DCM), GABAergic synapse, Hypertrophic cardiomyopathy (HCM), MAPK signaling pathway, Oxytocin signaling pathway, Synaptic vesicle cycle |
1件: 13 |
1002 |
Neurovax |
- |
- |
- |
- |
1件: 13 |
1003 |
Neurovax 300ug/ml dose for im injection |
- |
- |
- |
- |
1件: 13 |
1004 |
New formulation of rebif - human interferon beta-1a |
Human interferon beta |
- |
- |
- |
1件: 13 |
1005 |
Niacinamide |
Nicotinamide |
D00036 |
- |
- |
4件: 5, 6, 13, 67 |
1006 |
Nitrofurantoin |
Nitrofurantoin |
D00439 |
- |
- |
1件: 13 |
1007 |
Nivolumab |
Nivolumab |
D10316 |
1件: PDCD1 |
3件: Cell adhesion molecules (CAMs), PD-L1 expression and PD-1 checkpoint pathway in cancer, T cell receptor signaling pathway |
10件: 13, 26, 41, 46, 49, 50, 51, 53, 96, 97 |
1008 |
Nomegestrol |
Nomegestrol |
D07222 |
1件: PGR |
4件: Breast cancer, Estrogen signaling pathway, Oocyte meiosis, Progesterone-mediated oocyte maturation |
1件: 13 |
1009 |
Nomegestrol acetate |
Nomegestrol acetate |
D08281 |
1件: PGR |
4件: Breast cancer, Estrogen signaling pathway, Oocyte meiosis, Progesterone-mediated oocyte maturation |
1件: 13 |
1010 |
Non-pegylated interferon |
- |
- |
- |
- |
1件: 13 |
1011 |
Norethindrone |
Norethisterone |
D00182, D00953 |
1件: PGR |
4件: Breast cancer, Estrogen signaling pathway, Oocyte meiosis, Progesterone-mediated oocyte maturation |
4件: 13, 46, 49, 299 |
1012 |
Normal saline for injection |
- |
- |
- |
- |
1件: 13 |
1013 |
Novantrone*inf 2mg/ml 5ml |
Mitoxantrone |
D02166, D08224 |
2件: TOP2A, TOP2B |
1件: Platinum drug resistance |
1件: 13 |
1014 |
Npb-01 |
- |
- |
- |
- |
3件: 13, 14, 162 |
1015 |
Nt-ko-003 |
- |
- |
- |
- |
1件: 13 |
1016 |
Nu100 |
- |
- |
- |
- |
1件: 13 |
1017 |
Null |
- |
- |
- |
- |
17件: 6, 13, 14, 15, 28, 37, 46, 49, 51, 63, 86, 90, 96, 97, 107, 145, 271 |
1018 |
Nurown (msc-ntf cells) |
- |
- |
- |
- |
1件: 13 |
1019 |
Ocrelizumab |
Ocrelizumab |
D05218 |
1件: MS4A1 |
1件: Hematopoietic cell lineage |
3件: 13, 46, 49 |
1020 |
Ocrelizumab 300 mg |
Ocrelizumab |
D05218 |
1件: MS4A1 |
1件: Hematopoietic cell lineage |
1件: 13 |
1021 |
Ocrelizumab 300mg |
Ocrelizumab |
D05218 |
1件: MS4A1 |
1件: Hematopoietic cell lineage |
1件: 13 |
1022 |
Ocrelizumab 300mg /10ml |
Ocrelizumab |
D05218 |
1件: MS4A1 |
1件: Hematopoietic cell lineage |
1件: 13 |
1023 |
Ocrelizumab 300mg/10ml |
Ocrelizumab |
D05218 |
1件: MS4A1 |
1件: Hematopoietic cell lineage |
1件: 13 |
1024 |
Ocrelizumab 600 mg |
Ocrelizumab |
D05218 |
1件: MS4A1 |
1件: Hematopoietic cell lineage |
1件: 13 |
1025 |
Ocrelizumab dose 1 |
Ocrelizumab |
D05218 |
1件: MS4A1 |
1件: Hematopoietic cell lineage |
1件: 13 |
1026 |
Ocrelizumab dose 2 and dose 3 |
Ocrelizumab |
D05218 |
1件: MS4A1 |
1件: Hematopoietic cell lineage |
1件: 13 |
1027 |
Ocrevus |
Ocrelizumab |
D05218 |
1件: MS4A1 |
1件: Hematopoietic cell lineage |
1件: 13 |
1028 |
Octagam 5% |
- |
- |
- |
- |
2件: 13, 65 |
1029 |
Octagam 50 mg/ml |
- |
- |
- |
- |
1件: 13 |
1030 |
Ofatumumab |
Ofatumumab |
D09314 |
1件: MS4A1 |
1件: Hematopoietic cell lineage |
3件: 13, 35, 46 |
1031 |
Ofatumumab 100 |
Ofatumumab |
D09314 |
1件: MS4A1 |
1件: Hematopoietic cell lineage |
1件: 13 |
1032 |
Ofatumumab 300 |
Ofatumumab |
D09314 |
1件: MS4A1 |
1件: Hematopoietic cell lineage |
1件: 13 |
1033 |
Ofatumumab 30mg |
Ofatumumab |
D09314 |
1件: MS4A1 |
1件: Hematopoietic cell lineage |
1件: 13 |
1034 |
Ofatumumab 3mg |
Ofatumumab |
D09314 |
1件: MS4A1 |
1件: Hematopoietic cell lineage |
1件: 13 |
1035 |
Ofatumumab 60mg |
Ofatumumab |
D09314 |
1件: MS4A1 |
1件: Hematopoietic cell lineage |
1件: 13 |
1036 |
Ofatumumab 700 |
Ofatumumab |
D09314 |
1件: MS4A1 |
1件: Hematopoietic cell lineage |
1件: 13 |
1037 |
Ofatumumab subcutaneous injection |
Ofatumumab |
D09314 |
1件: MS4A1 |
1件: Hematopoietic cell lineage |
1件: 13 |
1038 |
Oleic acid |
Oleic acid |
D02315 |
- |
- |
1件: 13 |
1039 |
Oleovit d3 14.400 iu/ml oral drops, solution |
- |
- |
- |
- |
1件: 13 |
1040 |
Olesoxime (tro19622) |
Tro19622 |
- |
- |
- |
1件: 13 |
1041 |
Olive |
Olea europaea leaf |
- |
- |
- |
3件: 13, 49, 53 |
1042 |
Olive oil |
Olive oil |
D03311 |
- |
- |
3件: 13, 49, 53 |
1043 |
Omb157 |
- |
- |
- |
- |
1件: 13 |
1044 |
Omega 3 |
Omega-3 fatty acids |
- |
- |
- |
2件: 13, 299 |
1045 |
Omega 3 fatty acids |
Omega-3 fatty acids |
- |
- |
- |
1件: 13 |
1046 |
Omega-3 |
Omega-3 fatty acids |
- |
- |
- |
7件: 13, 46, 49, 66, 79, 96, 299 |
1047 |
Omega-3 fatty acids |
Omega-3 fatty acids |
- |
- |
- |
2件: 13, 79 |
1048 |
Omeprazole |
Omeprazole |
D00455, D01207, D05259, D05261 |
2件: ATP4A, ATP4B |
4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation |
15件: 6, 8, 13, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299 |
1049 |
Onabotulinumtoxina |
Botulinum toxin type a |
D00783 |
1件: SNAP25 |
2件: Insulin secretion, Synaptic vesicle cycle |
3件: 6, 13, 226 |
1050 |
Ono-4641 |
- |
- |
- |
- |
1件: 13 |
1051 |
Ono-4641/msc2430913a |
- |
- |
- |
- |
1件: 13 |
1052 |
Opicinumab |
Opicinumab |
- |
- |
- |
1件: 13 |
1053 |
Oral lipoic acid (la) |
Lipoic acid |
D00048, D00086 |
- |
- |
1件: 13 |
1054 |
Oral thc |
- |
- |
- |
- |
1件: 13 |
1055 |
Ory2001 |
- |
- |
- |
- |
1件: 13 |
1056 |
Os440 |
- |
- |
- |
- |
1件: 13 |
1057 |
Other disease-modifying therapy |
- |
- |
- |
- |
1件: 13 |
1058 |
Other h1 antagonist |
- |
- |
- |
- |
1件: 13 |
1059 |
Other nervous system drugs |
- |
- |
- |
- |
2件: 6, 13 |
1060 |
Ovastat |
Treosulfan |
D07253 |
- |
- |
2件: 13, 65 |
1061 |
Ovastat 1000 |
Treosulfan |
D07253 |
- |
- |
1件: 13 |
1062 |
Ovastat 5000 |
Treosulfan |
D07253 |
- |
- |
1件: 13 |
1063 |
Oxcarbazepine |
Oxcarbazepine |
D00533 |
5件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A |
3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
1件: 13 |
1064 |
Oxine |
Oxyquinoline |
D05321 |
- |
- |
1件: 13 |
1065 |
Oxycodone |
Oxycodone |
D03783, D05312, D05462 |
3件: OPRD1, OPRK1, OPRM1 |
5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
7件: 6, 13, 46, 70, 226, 231, 298 |
1066 |
Ozanimod |
Ozanimod |
D10968 |
5件: S1PR1, S1PR2, S1PR3, S1PR4, S1PR5 |
3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway |
3件: 13, 96, 97 |
1067 |
Ozanimod 0.5 mg |
Ozanimod |
D10968 |
5件: S1PR1, S1PR2, S1PR3, S1PR4, S1PR5 |
3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway |
1件: 13 |
1068 |
Ozanimod 1 mg |
Ozanimod |
D10968 |
5件: S1PR1, S1PR2, S1PR3, S1PR4, S1PR5 |
3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway |
1件: 13 |
1069 |
Ozanimod hydrochloride |
Ozanimod |
D10968 |
5件: S1PR1, S1PR2, S1PR3, S1PR4, S1PR5 |
3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway |
3件: 13, 96, 97 |
1070 |
Palifermin |
Palifermin |
D05338 |
1件: FGFR2 |
12件: Central carbon metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Gastric cancer, MAPK signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Signaling pathways regulating pluripotency of stem cells |
4件: 13, 38, 39, 65 |
1071 |
Pantoprazole |
Pantoprazole |
D02593, D05353 |
2件: ATP4A, ATP4B |
4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation |
2件: 13, 65 |
1072 |
Paracetamol |
Acetaminophen |
D00217 |
2件: PTGS1, PTGS2 |
21件: Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
5件: 3, 6, 13, 35, 46 |
1073 |
Paroxetine |
Paroxetine |
D02260, D02362, D05374, D05375 |
1件: SLC6A4 |
2件: Serotonergic synapse, Synaptic vesicle cycle |
3件: 6, 13, 46 |
1074 |
Part a: 100 mg/ml gsk2618960 |
- |
- |
- |
- |
1件: 13 |
1075 |
Part b: dose of gsk2618960 decided from part a |
- |
- |
- |
- |
1件: 13 |
1076 |
Part c: dose of gsk2618960 decided from part a and b |
- |
- |
- |
- |
1件: 13 |
1077 |
Peg-liposomal prednisolone sodium phosphate |
Prednisolone |
D00472, D00980, D00981, D00982, D01239, D01998, D02156, D03301 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
2件: 13, 97 |
1078 |
Peginterferon beta-1a |
- |
- |
- |
- |
1件: 13 |
1079 |
Pegylated intereron beta-1a |
- |
- |
- |
- |
1件: 13 |
1080 |
Pegylated interferon beta-1a |
Human interferon beta |
- |
- |
- |
1件: 13 |
1081 |
Pending |
- |
- |
- |
- |
3件: 13, 113, 302 |
1082 |
Pent |
Pentaerythritol tetranitrate |
D01721 |
- |
- |
1件: 13 |
1083 |
Pet with 11c-flumazenil |
Flumazenil |
D00697 |
16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
1件: 13 |
1084 |
Pf-06342674 0.25 mg/kg |
- |
- |
- |
- |
1件: 13 |
1085 |
Pf-06342674 1.5 mg/kg |
- |
- |
- |
- |
1件: 13 |
1086 |
Pf-06342674 6.0 mg/kg |
- |
- |
- |
- |
1件: 13 |
1087 |
Phenylcyclopropylamine derivatives and dual lsd1/mao-b (lysine-specific demethylase 1 and monoamine oxidase-b) inhibitor |
L-lysine |
D02304 |
- |
- |
1件: 13 |
1088 |
Phenytoin |
Phenytoin |
D00512, D02103 |
5件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A |
3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
1件: 13 |
1089 |
Phosphate |
Phosphate ion |
- |
- |
- |
29件: 2, 3, 11, 12, 13, 28, 36, 46, 49, 51, 53, 60, 62, 65, 70, 78, 81, 83, 90, 96, 97, 164, 235, 256, 283, 284, 285, 286, 299 |
1090 |
Pi-2301 |
- |
- |
- |
- |
1件: 13 |
1091 |
Pioglitazone |
Pioglitazone |
D00945, D08378 |
1件: PPARG |
9件: AMPK signaling pathway, Huntington disease, Longevity regulating pathway, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer |
17件: 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 |
1092 |
Pixantrone |
Pixantrone |
D05522 |
2件: TOP2A, TOP2B |
1件: Platinum drug resistance |
2件: 11, 13 |
1093 |
Pl 04515/0127 |
- |
- |
- |
- |
1件: 13 |
1094 |
Pl 12762/0049 |
- |
- |
- |
- |
1件: 13 |
1095 |
Placebo |
- |
- |
- |
- |
20件: 3, 6, 13, 14, 40, 46, 49, 50, 51, 66, 67, 79, 85, 86, 88, 96, 97, 144, 149, 226 |
1096 |
Platelet transfusion |
- |
- |
- |
- |
1件: 13 |
1097 |
Plegridy |
Peginterferon beta-1a |
D10483 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
1098 |
Plegridy (peginterferon beta-1a), biogen idec ltd |
Peginterferon beta-1a |
D10483 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
1099 |
Plegridy 125 micrograms |
Peginterferon beta-1a |
D10483 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
1100 |
Pleneva tm bgc20-0134 |
- |
- |
- |
- |
1件: 13 |
1101 |
Plovamer acetate |
Acetate |
- |
- |
- |
1件: 13 |
1102 |
Plp peptide |
- |
- |
- |
- |
1件: 13 |
1103 |
Pneumovax ii |
- |
- |
- |
- |
1件: 13 |
1104 |
Pnu-215062 sodium salt |
- |
- |
- |
- |
1件: 13 |
1105 |
Polyphenon e |
- |
- |
- |
- |
2件: 13, 36 |
1106 |
Ponesimod |
Ponesimod |
D11215 |
1件: S1PR1 |
3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway |
1件: 13 |
1107 |
Ponesimod 10 mg |
Ponesimod |
D11215 |
1件: S1PR1 |
3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway |
1件: 13 |
1108 |
Ponesimod 20 mg |
Ponesimod |
D11215 |
1件: S1PR1 |
3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway |
1件: 13 |
1109 |
Ponesimod 40 mg |
Ponesimod |
D11215 |
1件: S1PR1 |
3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway |
1件: 13 |
1110 |
Pravastatin |
Pravastatin |
D00893, D08410 |
1件: HMGCR |
4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
9件: 13, 46, 49, 67, 79, 96, 164, 265, 333 |
1111 |
Prebiotics (prebiotin prebiotic fiber stick pac) |
- |
- |
- |
- |
1件: 13 |
1112 |
Prednisolone |
Prednisolone |
D00472, D00980, D00981, D00982, D01239, D01998, D02156, D03301 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
38件: 11, 13, 25, 26, 35, 38, 39, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 113, 145, 162, 222, 269, 271, 296, 299, 300 |
1113 |
Prednisolone sodium phosphate |
Prednisolone |
D00472, D00980, D00981, D00982, D01239, D01998, D02156, D03301 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
2件: 13, 97 |
1114 |
Prednisone |
Prednisone |
D00473 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
43件: 2, 11, 13, 14, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 81, 84, 85, 86, 95, 96, 97, 113, 162, 164, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331 |
1115 |
Pregabalin |
Pregabalin |
D02716 |
4件: CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4 |
7件: Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cardiac muscle contraction, Dilated cardiomyopathy (DCM), Hypertrophic cardiomyopathy (HCM), MAPK signaling pathway, Oxytocin signaling pathway |
5件: 13, 36, 46, 70, 298 |
1116 |
Prepulsid |
- |
- |
- |
- |
1件: 13 |
1117 |
Prn2246 |
- |
- |
- |
- |
1件: 13 |
1118 |
Probiotics (visbiome®) |
- |
- |
- |
- |
1件: 13 |
1119 |
Prohance (gadoteridol) |
Gadoteridol |
D01137 |
- |
- |
1件: 13 |
1120 |
Prolonged-release fampridine |
Dalfampridine |
D04127 |
2件: KCNA4, KCND2 |
3件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse |
1件: 13 |
1121 |
Prophylactic vaccine (tetanus, diphtheria, pertussis, poliomyelitis, influenza, hepatitis a, hepatitis b, tick-borne encephalitis, meningococcal, pneumococcal) |
- |
- |
- |
- |
1件: 13 |
1122 |
Provigil |
Modafinil |
D01832 |
- |
- |
1件: 13 |
1123 |
Provigil (modafinil) |
Modafinil |
D01832 |
- |
- |
1件: 13 |
1124 |
Prucalopride |
Prucalopride |
D09205 |
1件: HTR4 |
4件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Serotonergic synapse, cAMP signaling pathway |
3件: 13, 51, 96 |
1125 |
Ptl201 |
- |
- |
- |
- |
1件: 13 |
1126 |
Quetiapine |
Quetiapine |
D00458, D08456 |
2件: DRD2, HTR2A |
11件: Alcoholism, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Serotonergic synapse, cAMP signaling pathway |
2件: 6, 13 |
1127 |
Quinidine |
Quinidine |
D00642, D00643, D02272, D08458 |
5件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A |
3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
3件: 2, 8, 13 |
1128 |
R lipoic acid |
Lipoic acid |
D00048, D00086 |
- |
- |
1件: 13 |
1129 |
Rabbit |
Rabbit |
- |
- |
- |
7件: 13, 49, 51, 60, 65, 96, 285 |
1130 |
Rabbit human t lymphocyte immunoglobulin |
Rabbit |
- |
- |
- |
2件: 13, 60 |
1131 |
Ralenova |
Mitoxantrone |
D02166, D08224 |
2件: TOP2A, TOP2B |
1件: Platinum drug resistance |
1件: 13 |
1132 |
Raltegravir |
Raltegravir |
D06676 |
- |
- |
4件: 13, 26, 93, 265 |
1133 |
Ramatroban |
Ramatroban |
D01128 |
2件: PTGDR, TBXA2R |
3件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Platelet activation |
1件: 13 |
1134 |
Ranitidine |
Ranitidine |
D00422, D00673 |
1件: HRH2 |
3件: Calcium signaling pathway, Gastric acid secretion, Neuroactive ligand-receptor interaction |
2件: 13, 65 |
1135 |
Raptiva 100 mg/ml powder and solvent for solution for injection |
Efalizumab |
D03959 |
1件: ITGAL |
11件: Cell adhesion molecules (CAMs), Epstein-Barr virus infection, Human T-cell leukemia virus 1 infection, Leukocyte transendothelial migration, Malaria, Natural killer cell mediated cytotoxicity, Rap1 signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Staphylococcus aureus infection, Viral myocarditis |
7件: 11, 13, 46, 53, 61, 95, 96 |
1136 |
Ratg |
- |
- |
- |
- |
2件: 13, 51 |
1137 |
Rc18 160 mg |
- |
- |
- |
- |
2件: 13, 53 |
1138 |
Rebif |
Interferon beta-1a |
D04554 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
1139 |
Rebif (ifn beta-1a subcutaneous three times per week) |
- |
- |
- |
- |
1件: 13 |
1140 |
Rebif (ifn ß-1a subcutaneous three times per week) |
- |
- |
- |
- |
1件: 13 |
1141 |
Rebif (ifnbeta-1b) |
- |
- |
- |
- |
1件: 13 |
1142 |
Rebif (ifnß-1b) |
- |
- |
- |
- |
1件: 13 |
1143 |
Rebif (interferon beta 1a) |
Interferon beta-1a |
D04554 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
1144 |
Rebif (interferon beta-1a) |
Human interferon beta |
- |
- |
- |
1件: 13 |
1145 |
Rebif (interferon beta-1a), merck serono europe ltd |
Human interferon beta |
- |
- |
- |
1件: 13 |
1146 |
Rebif 22 |
Interferon beta-1a |
D04554 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
1147 |
Rebif 22 micrograms |
Interferon beta-1a |
D04554 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
1148 |
Rebif 22 y 44 mcg |
Interferon beta-1a |
D04554 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
1149 |
Rebif 22® |
- |
- |
- |
- |
1件: 13 |
1150 |
Rebif 44 |
Interferon beta-1a |
D04554 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
1151 |
Rebif 44 microgramos solución inyectable |
Interferon beta-1a |
D04554 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
1152 |
Rebif 44 micrograms |
Interferon beta-1a |
D04554 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
1153 |
Rebif 44 µg |
Interferon beta-1a |
D04554 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
1154 |
Rebif 44® |
- |
- |
- |
- |
1件: 13 |
1155 |
Rebif 8,8 µg, rebif 22µg |
Interferon beta-1a |
D04554 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
1156 |
Rebif new formulation + ibuprofen prn |
Ibuprofen |
D00126, D01122, D04490, D06606 |
2件: PTGS1, PTGS2 |
21件: Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
1件: 13 |
1157 |
Rebif new formulation + prophylactic ibuprofen |
Ibuprofen |
D00126, D01122, D04490, D06606 |
2件: PTGS1, PTGS2 |
21件: Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
1件: 13 |
1158 |
Rebif new formulation 44mcg multidose cartridge |
Interferon beta-1a |
D04554 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
1159 |
Rebif new formulation non titrated |
- |
- |
- |
- |
1件: 13 |
1160 |
Rebif new formulation titrated |
- |
- |
- |
- |
1件: 13 |
1161 |
Rebif sc 12sir 12000000ui44mcg |
Interferon beta-1a |
D04554 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
1162 |
Rebif sc 12sir 6000000ui 22mcg |
Interferon beta-1a |
D04554 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
1163 |
Rebif*sc 12sir 12000000ui44mcg |
Interferon beta-1a |
D04554 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
1164 |
Rebif® |
Interferon beta-1a |
D04554 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
1165 |
Rebif® (clone 484-39) |
- |
- |
- |
- |
1件: 13 |
1166 |
Rebif® new formulation |
- |
- |
- |
- |
1件: 13 |
1167 |
Rebif® new formulation (rnf) |
- |
- |
- |
- |
1件: 13 |
1168 |
Rebif® new formulation (rnf) using rebismarttm |
- |
- |
- |
- |
1件: 13 |
1169 |
Recombinant human alpha b-crystallin |
- |
- |
- |
- |
1件: 13 |
1170 |
Recombinant human erythropoietin |
Erythropoietin |
D03231 |
1件: EPOR |
5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
1件: 13 |
1171 |
Recombinant human interferon beta |
Human interferon beta |
- |
- |
- |
1件: 13 |
1172 |
Recombinant humanized anti-alpha 4 integrin antibody |
- |
- |
- |
- |
1件: 13 |
1173 |
Recombinant interferon beta-1b |
Interferon beta-1b |
D00746 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
1174 |
Repository corticotropin injection |
Corticotropin |
D00146 |
1件: MC2R |
5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
5件: 2, 13, 46, 84, 222 |
1175 |
Revaxis |
- |
- |
- |
- |
1件: 13 |
1176 |
Rg2077 (ctla4-igg4m) |
- |
- |
- |
- |
1件: 13 |
1177 |
Rhb-104 |
- |
- |
- |
- |
2件: 13, 96 |
1178 |
Rhepo |
- |
- |
- |
- |
1件: 13 |
1179 |
Rhifn beta-1b |
- |
- |
- |
- |
1件: 13 |
1180 |
Rhigf-1 (cep-151) |
- |
- |
- |
- |
1件: 13 |
1181 |
Rhigm22 |
- |
- |
- |
- |
1件: 13 |
1182 |
Rhumab 2h7 |
- |
- |
- |
- |
3件: 13, 46, 49 |
1183 |
Rhumab to il-17a (igg1-k-class) |
- |
- |
- |
- |
2件: 13, 46 |
1184 |
Rhuph20 |
- |
- |
- |
- |
2件: 13, 14 |
1185 |
Riboflavin |
Riboflavin |
D00050, D01622, D01913 |
- |
- |
8件: 13, 38, 46, 96, 97, 162, 168, 265 |
1186 |
Rifampin |
Rifampicin |
D00211 |
- |
- |
5件: 6, 13, 84, 86, 299 |
1187 |
Riluzole |
Riluzole |
D00775 |
14件: GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
20件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term depression, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Retrograde endocannabinoid signaling, Systemic lupus erythematosus, Transcriptional misregulation in cancer, cAMP signaling pathway |
7件: 2, 3, 5, 8, 13, 17, 206 |
1188 |
Ritalin |
Methylphenidate |
D01296, D04999 |
2件: SLC6A2, SLC6A3 |
6件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Synaptic vesicle cycle |
2件: 6, 13 |
1189 |
Ritalin la 20mg capsules |
Methylphenidate |
D01296, D04999 |
2件: SLC6A2, SLC6A3 |
6件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Synaptic vesicle cycle |
1件: 13 |
1190 |
Ritalin la 30mg capsules |
Methylphenidate |
D01296, D04999 |
2件: SLC6A2, SLC6A3 |
6件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Synaptic vesicle cycle |
1件: 13 |
1191 |
Ritalin la 40mg capsules |
Methylphenidate |
D01296, D04999 |
2件: SLC6A2, SLC6A3 |
6件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Synaptic vesicle cycle |
1件: 13 |
1192 |
Rituximab |
Rituximab |
D02994 |
1件: MS4A1 |
1件: Hematopoietic cell lineage |
42件: 11, 13, 14, 17, 35, 36, 43, 44, 45, 46, 49, 50, 51, 52, 53, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 162, 222, 223, 229, 256, 271, 283, 284, 285, 288, 300, 331 |
1193 |
Rituximab infusion |
Rituximab |
D02994 |
1件: MS4A1 |
1件: Hematopoietic cell lineage |
2件: 13, 222 |
1194 |
Rituximab it |
Rituximab |
D02994 |
1件: MS4A1 |
1件: Hematopoietic cell lineage |
1件: 13 |
1195 |
Rituximab iv |
Rituximab |
D02994 |
1件: MS4A1 |
1件: Hematopoietic cell lineage |
1件: 13 |
1196 |
Rivastigmin |
- |
- |
- |
- |
1件: 13 |
1197 |
Rivastigmine |
Rivastigmine |
D02558, D03822 |
1件: ACHE |
2件: Cholinergic synapse, Glycerophospholipid metabolism |
3件: 5, 6, 13 |
1198 |
Rivastigmine transdermal patch |
Rivastigmine |
D02558, D03822 |
1件: ACHE |
2件: Cholinergic synapse, Glycerophospholipid metabolism |
2件: 6, 13 |
1199 |
Rns60 |
- |
- |
- |
- |
2件: 2, 13 |
1200 |
Rns60 125 ml |
- |
- |
- |
- |
1件: 13 |
1201 |
Rns60 250 ml |
- |
- |
- |
- |
1件: 13 |
1202 |
Ro 496-4913/f07 |
- |
- |
- |
- |
1件: 13 |
1203 |
Ro0506997 |
- |
- |
- |
- |
2件: 13, 46 |
1204 |
Ro4964913 |
- |
- |
- |
- |
1件: 13 |
1205 |
Ro4964913 f07 |
- |
- |
- |
- |
1件: 13 |
1206 |
Ro4964913/f03 |
- |
- |
- |
- |
1件: 13 |
1207 |
Ro4964913/f07 |
- |
- |
- |
- |
1件: 13 |
1208 |
Ro4964913/f07-01 |
- |
- |
- |
- |
1件: 13 |
1209 |
Ro4964913/f07-01 (commercial) |
- |
- |
- |
- |
1件: 13 |
1210 |
Ro4964913/f07-01 (development) |
- |
- |
- |
- |
1件: 13 |
1211 |
Rolipram |
Rolipram |
D01783 |
4件: PDE4A, PDE4B, PDE4C, PDE4D |
5件: Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway |
2件: 8, 13 |
1212 |
Rpc-1063 |
- |
- |
- |
- |
1件: 13 |
1213 |
Rpc1063 |
- |
- |
- |
- |
3件: 13, 96, 97 |
1214 |
Rtl1000 (recombinant t cell receptor ligand) |
- |
- |
- |
- |
1件: 13 |
1215 |
S-warfarin |
Warfarin |
D00564, D01280, D08682 |
2件: NQO1, VKORC1 |
5件: Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Metabolic pathways, Pathways in cancer, Ubiquinone and other terpenoid-quinone biosynthesis |
1件: 13 |
1216 |
Sa237 |
- |
- |
- |
- |
1件: 13 |
1217 |
Sa237-120 pfs with nsd |
- |
- |
- |
- |
1件: 13 |
1218 |
Sa237-120/vial |
- |
- |
- |
- |
1件: 13 |
1219 |
Saline |
Sodium chloride |
D02056 |
- |
- |
10件: 6, 13, 17, 53, 67, 78, 86, 97, 168, 299 |
1220 |
Sar339658 |
- |
- |
- |
- |
2件: 13, 97 |
1221 |
Sar442168 |
- |
- |
- |
- |
1件: 13 |
1222 |
Sativex |
Dronabinol |
D00306 |
2件: CNR1, CNR2 |
4件: Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis |
2件: 2, 13 |
1223 |
Sativex oromucosal spray |
Dronabinol |
D00306 |
2件: CNR1, CNR2 |
4件: Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis |
1件: 13 |
1224 |
Sativex® |
- |
- |
- |
- |
1件: 13 |
1225 |
Satralizumab |
- |
- |
- |
- |
1件: 13 |
1226 |
Satralizumab (r-inn) |
- |
- |
- |
- |
1件: 13 |
1227 |
Sb-683699 |
- |
- |
- |
- |
1件: 13 |
1228 |
Sb683699 |
- |
- |
- |
- |
1件: 13 |
1229 |
Sc interferon beta-1a |
Human interferon beta |
- |
- |
- |
1件: 13 |
1230 |
Sc interferon beta-1b |
Human interferon beta |
- |
- |
- |
1件: 13 |
1231 |
Sc peginterferon beta-1a |
- |
- |
- |
- |
1件: 13 |
1232 |
Sclerolym |
- |
- |
- |
- |
1件: 13 |
1233 |
Seasonal quadrivalent influenza vaccine |
- |
- |
- |
- |
1件: 13 |
1234 |
Second-generation fumaric acid |
Fumaric acid |
D02308 |
- |
- |
1件: 13 |
1235 |
Secukinumab |
Secukinumab |
D09967 |
1件: IL17A |
5件: Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease (IBD), Rheumatoid arthritis, Th17 cell differentiation |
7件: 13, 37, 41, 46, 160, 269, 271 |
1236 |
Selenium |
Selenium |
- |
- |
- |
2件: 13, 278 |
1237 |
Sendoxan |
- |
- |
- |
- |
1件: 13 |
1238 |
Serum containing avonex |
- |
- |
- |
- |
1件: 13 |
1239 |
Serum free avonex |
- |
- |
- |
- |
1件: 13 |
1240 |
Sh u 555 c |
- |
- |
- |
- |
1件: 13 |
1241 |
Silodyx |
Silodosin |
D01965 |
1件: ADRA1A |
7件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
1件: 13 |
1242 |
Simethicone |
Simethicone |
D05841 |
- |
- |
2件: 13, 96 |
1243 |
Simvahexal® 40 mg filmtabletten |
- |
- |
- |
- |
1件: 13 |
1244 |
Simvastatin |
Simvastatin |
D00434 |
1件: HMGCR |
4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
19件: 6, 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 162, 195, 265, 298, 299, 310 |
1245 |
Simvastatin 40 mg film-coated tablets |
Simvastatin |
D00434 |
1件: HMGCR |
4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
1件: 13 |
1246 |
Simvastatin alternova |
Simvastatin |
D00434 |
1件: HMGCR |
4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
1件: 13 |
1247 |
Simvastatina |
Simvastatin |
D00434 |
1件: HMGCR |
4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
1件: 13 |
1248 |
Simvastatina sandoz 40 mg comprimidos recubiertos con película efg |
Simvastatin |
D00434 |
1件: HMGCR |
4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
1件: 13 |
1249 |
Simvastatine |
Simvastatin |
D00434 |
1件: HMGCR |
4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
2件: 6, 13 |
1250 |
Simvastatine sandoz 40 mg filmomhulde tabletten |
Simvastatin |
D00434 |
1件: HMGCR |
4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
1件: 13 |
1251 |
Simvastatine sandoz 40mg deelbare filmomhulde tabletten |
Simvastatin |
D00434 |
1件: HMGCR |
4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
1件: 13 |
1252 |
Sinvastatina sandoz 40 mg comprimidos revestidos por película |
- |
- |
- |
- |
1件: 13 |
1253 |
Siponimod |
Siponimod |
D11460 |
2件: S1PR1, S1PR5 |
3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway |
2件: 13, 50 |
1254 |
Siponimod 0.25 mg tablet |
Siponimod |
D11460 |
2件: S1PR1, S1PR5 |
3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway |
1件: 13 |
1255 |
Siponimod 0.5 mg tablet |
Siponimod |
D11460 |
2件: S1PR1, S1PR5 |
3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway |
1件: 13 |
1256 |
Siponimod 1 mg tablet |
Siponimod |
D11460 |
2件: S1PR1, S1PR5 |
3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway |
1件: 13 |
1257 |
Siponimod 2 mg tablet |
Siponimod |
D11460 |
2件: S1PR1, S1PR5 |
3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway |
1件: 13 |
1258 |
Sirolimus |
Sirolimus |
D00753 |
1件: MTOR |
43件: AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway |
30件: 13, 17, 34, 35, 36, 46, 51, 60, 62, 63, 65, 66, 67, 85, 89, 96, 98, 137, 157, 158, 192, 222, 277, 278, 279, 280, 281, 283, 285, 331 |
1259 |
Sivatin 40 mg film-coated tablets |
- |
- |
- |
- |
1件: 13 |
1260 |
Sivelestat |
Sivelestat |
D03788 |
1件: ELANE |
2件: Systemic lupus erythematosus, Transcriptional misregulation in cancer |
3件: 13, 85, 96 |
1261 |
Smderpept |
- |
- |
- |
- |
1件: 13 |
1262 |
Smoked cannabis |
Medical cannabis |
- |
- |
- |
1件: 13 |
1263 |
Sodium chlorid |
- |
- |
- |
- |
1件: 13 |
1264 |
Sodium chloride |
Sodium chloride |
D02056 |
- |
- |
13件: 6, 11, 13, 14, 34, 46, 51, 168, 193, 227, 228, 288, 299 |
1265 |
Sodium chloride solution |
Sodium chloride |
D02056 |
- |
- |
3件: 11, 13, 228 |
1266 |
Soliris |
Eculizumab |
D03940 |
1件: C5 |
7件: Complement and coagulation cascades, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Pertussis, Prion diseases, Staphylococcus aureus infection, Systemic lupus erythematosus |
7件: 11, 13, 14, 62, 109, 222, 223 |
1267 |
Solu-medrol |
Methylprednisolone |
D00407, D00751, D00979, D05000, D05001, D05002 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
2件: 13, 97 |
1268 |
Solu-moderin 1 g |
- |
- |
- |
- |
1件: 13 |
1269 |
Solumedrol |
- |
- |
- |
- |
1件: 13 |
1270 |
Somatorelin |
Somatorelin |
D08523 |
1件: GHRHR |
2件: Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction |
2件: 13, 78 |
1271 |
Spiropent |
- |
- |
- |
- |
1件: 13 |
1272 |
Sr-fampridine |
Dalfampridine |
D04127 |
2件: KCNA4, KCND2 |
3件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse |
1件: 13 |
1273 |
Ss-interferon |
- |
- |
- |
- |
1件: 13 |
1274 |
Standard gadolinium contrast |
Gadolinium |
- |
- |
- |
1件: 13 |
1275 |
Standard ms dmts |
- |
- |
- |
- |
1件: 13 |
1276 |
Standard of care |
- |
- |
- |
- |
8件: 6, 13, 14, 49, 51, 64, 79, 85 |
1277 |
Standard treatment with a conventional drug |
- |
- |
- |
- |
1件: 13 |
1278 |
Statin |
- |
- |
- |
- |
1件: 13 |
1279 |
Stem cell transplantation |
- |
- |
- |
- |
9件: 13, 19, 20, 46, 65, 90, 164, 234, 326 |
1280 |
Study drug |
- |
- |
- |
- |
2件: 6, 13 |
1281 |
Sub0750mig |
- |
- |
- |
- |
1件: 13 |
1282 |
Sub22282 |
- |
- |
- |
- |
1件: 13 |
1283 |
Sublingual tizanidine 12 mg |
Tizanidine |
D00776, D08611 |
3件: ADRA2A, ADRA2B, ADRA2C |
2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
1件: 13 |
1284 |
Sulfate |
Sulfate ion |
- |
- |
- |
22件: 2, 6, 11, 13, 26, 34, 36, 46, 49, 60, 61, 64, 66, 79, 86, 96, 222, 226, 265, 296, 297, 299 |
1285 |
Sunphenon |
- |
- |
- |
- |
2件: 13, 113 |
1286 |
Sunphenon egcg |
Epigallocatechin gallate |
- |
- |
- |
3件: 13, 17, 113 |
1287 |
Sunphenon egcg tm |
Epigallocatechin gallate |
- |
- |
- |
1件: 13 |
1288 |
Suspension media |
- |
- |
- |
- |
1件: 13 |
1289 |
Sustained-release oral dalfampridine |
Dalfampridine |
D04127 |
2件: KCNA4, KCND2 |
3件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse |
1件: 13 |
1290 |
Suvorexant |
Suvorexant |
D10082 |
2件: HCRTR1, HCRTR2 |
1件: Neuroactive ligand-receptor interaction |
3件: 5, 6, 13 |
1291 |
T cell vaccination |
- |
- |
- |
- |
1件: 13 |
1292 |
T-cell vaccination |
- |
- |
- |
- |
1件: 13 |
1293 |
Taci-fc5 |
Atacicept |
D09704 |
2件: TNFSF13, TNFSF13B |
4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis |
3件: 13, 46, 49 |
1294 |
Tacrolimus |
Tacrolimus |
D00107, D08556 |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
30件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
29件: 2, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 228, 283, 284, 299 |
1295 |
Tanakan |
Ginkgo biloba |
- |
- |
- |
1件: 13 |
1296 |
Tarenflurbil |
Tarenflurbil |
D09010 |
4件: APH1A, NCSTN, PSEN1, PSENEN |
5件: Alzheimer disease, Human papillomavirus infection, Neurotrophin signaling pathway, Notch signaling pathway, Wnt signaling pathway |
1件: 13 |
1297 |
Targretin |
Bexarotene |
D03106 |
3件: RXRA, RXRB, RXRG |
15件: Adipocytokine signaling pathway, Bile secretion, Gastric cancer, Hepatitis C, Non-alcoholic fatty liver disease (NAFLD), Non-small cell lung cancer, PI3K-Akt signaling pathway, PPAR signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Thyroid cancer, Thyroid hormone signaling pathway, Transcriptional misregulation in cancer |
1件: 13 |
1298 |
Taurine |
Taurine |
D00047 |
- |
- |
1件: 13 |
1299 |
Tauroursodeoxycholic acid |
Tauroursodeoxycholic acid |
- |
- |
- |
4件: 2, 13, 93, 299 |
1300 |
Tcelna |
- |
- |
- |
- |
1件: 13 |
1301 |
Tecfidera |
Dimethyl fumarate |
D03846 |
1件: KEAP1 |
4件: Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Pathways in cancer, Ubiquitin mediated proteolysis |
1件: 13 |
1302 |
Tecfidera (bg12) |
- |
- |
- |
- |
1件: 13 |
1303 |
Tecfidera® |
Dimethyl fumarate |
D03846 |
1件: KEAP1 |
4件: Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Pathways in cancer, Ubiquitin mediated proteolysis |
1件: 13 |
1304 |
Tecfidera® 120 mg |
Dimethyl fumarate |
D03846 |
1件: KEAP1 |
4件: Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Pathways in cancer, Ubiquitin mediated proteolysis |
1件: 13 |
1305 |
Tecfidera® 120mg magensaftresistente hartkapseln |
Dimethyl fumarate |
D03846 |
1件: KEAP1 |
4件: Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Pathways in cancer, Ubiquitin mediated proteolysis |
1件: 13 |
1306 |
Tecfidera® 240 mg |
Dimethyl fumarate |
D03846 |
1件: KEAP1 |
4件: Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Pathways in cancer, Ubiquitin mediated proteolysis |
1件: 13 |
1307 |
Tecfidera® 240mg magensaftresistente hartkapseln |
Dimethyl fumarate |
D03846 |
1件: KEAP1 |
4件: Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Pathways in cancer, Ubiquitin mediated proteolysis |
1件: 13 |
1308 |
Tecifdera (dimethyl fumarate) |
Dimethyl fumarate |
D03846 |
1件: KEAP1 |
4件: Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Pathways in cancer, Ubiquitin mediated proteolysis |
1件: 13 |
1309 |
Temsirolimus |
Temsirolimus |
D06068 |
1件: MTOR |
43件: AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway |
4件: 13, 34, 89, 331 |
1310 |
Temsirolimus tablets |
Temsirolimus |
D06068 |
1件: MTOR |
43件: AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway |
1件: 13 |
1311 |
Teriflunomide |
Teriflunomide |
D10172 |
1件: DHODH |
2件: Metabolic pathways, Pyrimidine metabolism |
2件: 13, 25 |
1312 |
Teriflunomide (hmr1726) |
Teriflunomide |
D10172 |
1件: DHODH |
2件: Metabolic pathways, Pyrimidine metabolism |
1件: 13 |
1313 |
Teriflunomide 14 mg |
Teriflunomide |
D10172 |
1件: DHODH |
2件: Metabolic pathways, Pyrimidine metabolism |
1件: 13 |
1314 |
Teriflunomide 14 mg oral tablet [aubagio] |
Teriflunomide |
D10172 |
1件: DHODH |
2件: Metabolic pathways, Pyrimidine metabolism |
1件: 13 |
1315 |
Teriflunomide hmr1726 |
Teriflunomide |
D10172 |
1件: DHODH |
2件: Metabolic pathways, Pyrimidine metabolism |
1件: 13 |
1316 |
Teriflunomide orally |
Teriflunomide |
D10172 |
1件: DHODH |
2件: Metabolic pathways, Pyrimidine metabolism |
1件: 13 |
1317 |
Testosterone |
Testosterone |
D00075, D00957, D00958, D00959, D06085, D06087 |
1件: AR |
3件: Oocyte meiosis, Pathways in cancer, Prostate cancer |
7件: 1, 2, 3, 13, 78, 113, 265 |
1318 |
Testosterone undecanoate |
Testosterone undecanoate |
D06087 |
1件: AR |
3件: Oocyte meiosis, Pathways in cancer, Prostate cancer |
1件: 13 |
1319 |
Tetanus diphtheria toxoid vaccine (td) |
- |
- |
- |
- |
1件: 13 |
1320 |
Tetanus diphtheria toxoids vaccine |
- |
- |
- |
- |
1件: 13 |
1321 |
Tetanus toxoid (tt) containing vaccine (td, tdap) |
- |
- |
- |
- |
1件: 13 |
1322 |
Tetracycline |
Tetracycline |
D00201 |
- |
- |
4件: 13, 46, 53, 97 |
1323 |
Tetracycline - statin - antimycotic |
Tetracycline |
D00201 |
- |
- |
1件: 13 |
1324 |
Tetrahydrocannabinol |
Dronabinol |
D00306 |
2件: CNR1, CNR2 |
4件: Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis |
2件: 13, 298 |
1325 |
Tg-1101 |
- |
- |
- |
- |
1件: 13 |
1326 |
Thiamine |
Thiamine |
D08580 |
- |
- |
2件: 13, 265 |
1327 |
Thioplex |
- |
- |
- |
- |
1件: 13 |
1328 |
Thiotepa |
Thiotepa |
D00583 |
- |
- |
11件: 13, 19, 20, 28, 51, 60, 65, 85, 96, 164, 284 |
1329 |
Thymoglobuline |
- |
- |
- |
- |
4件: 13, 36, 51, 65 |
1330 |
Tissue selective estrogen complex |
- |
- |
- |
- |
1件: 13 |
1331 |
Tizanidine |
Tizanidine |
D00776, D08611 |
3件: ADRA2A, ADRA2B, ADRA2C |
2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
1件: 13 |
1332 |
Tizanidine (sublingual or oral) |
Tizanidine |
D00776, D08611 |
3件: ADRA2A, ADRA2B, ADRA2C |
2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
1件: 13 |
1333 |
Tizanidine hydrochloride capsule |
Tizanidine |
D00776, D08611 |
3件: ADRA2A, ADRA2B, ADRA2C |
2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
1件: 13 |
1334 |
Tmp001 |
- |
- |
- |
- |
1件: 13 |
1335 |
Tocilizumab |
Tocilizumab |
D02596 |
1件: IL6R |
11件: Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease (NAFLD), PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
16件: 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |
1336 |
Tocilizumab injection |
Tocilizumab |
D02596 |
1件: IL6R |
11件: Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease (NAFLD), PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
1件: 13 |
1337 |
Tocopherol |
Tocopherol |
D02332 |
- |
- |
3件: 13, 49, 257 |
1338 |
Tolerogenic dendritic cells (toldc) |
- |
- |
- |
- |
1件: 13 |
1339 |
Tolerogenic dendritic cells loaded with myelin peptides |
- |
- |
- |
- |
1件: 13 |
1340 |
Tolperisone |
Tolperisone |
D08617 |
- |
- |
1件: 13 |
1341 |
Tolperisone hc1 |
Tolperisone |
D08617 |
- |
- |
1件: 13 |
1342 |
Tolperisone hcl |
Tolperisone |
D08617 |
- |
- |
1件: 13 |
1343 |
Tolpersan |
- |
- |
- |
- |
1件: 13 |
1344 |
Tolposan |
- |
- |
- |
- |
1件: 13 |
1345 |
Topical preparation h arm |
- |
- |
- |
- |
1件: 13 |
1346 |
Torvast*10cpr 10mg |
- |
- |
- |
- |
1件: 13 |
1347 |
Tovaxin |
- |
- |
- |
- |
1件: 13 |
1348 |
Tovaxin autologous t cell vaccine |
- |
- |
- |
- |
1件: 13 |
1349 |
Tracleer |
Bosentan |
D01227, D07538 |
2件: EDNRA, EDNRB |
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
8件: 13, 51, 84, 85, 86, 88, 210, 211 |
1350 |
Trancopal dolo |
- |
- |
- |
- |
1件: 13 |
1351 |
Treosulfan |
Treosulfan |
D07253 |
- |
- |
3件: 13, 19, 65 |
1352 |
Trichuris suis eggs |
- |
- |
- |
- |
3件: 13, 96, 97 |
1353 |
Trichuris suis ova |
- |
- |
- |
- |
4件: 13, 46, 96, 97 |
1354 |
Trichuris suis ova (eggs), embryonated, viable |
- |
- |
- |
- |
1件: 13 |
1355 |
Trileptal |
Oxcarbazepine |
D00533 |
5件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A |
3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
1件: 13 |
1356 |
Triomar™ (omega-3 fatty acids) |
Omega-3 fatty acids |
- |
- |
- |
1件: 13 |
1357 |
Tro19622 |
Tro19622 |
- |
- |
- |
3件: 2, 3, 13 |
1358 |
Tt vaccine |
- |
- |
- |
- |
1件: 13 |
1359 |
Tv-5010 |
Glatiramer |
D04318 |
20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G |
32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease (IBD), Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
1件: 13 |
1360 |
Tv-5600 |
- |
- |
- |
- |
2件: 13, 96 |
1361 |
Tylenol pill |
- |
- |
- |
- |
1件: 13 |
1362 |
Tysabri |
Natalizumab |
D06886 |
1件: ITGA4 |
14件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection |
3件: 13, 25, 63 |
1363 |
Tysabri 300 mg concentrate for solution for infusion |
Natalizumab |
D06886 |
1件: ITGA4 |
14件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection |
1件: 13 |
1364 |
Tysabri 300 mg solution à diluer pour perfusion |
Natalizumab |
D06886 |
1件: ITGA4 |
14件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection |
1件: 13 |
1365 |
Tysabri and avonex |
- |
- |
- |
- |
1件: 13 |
1366 |
Tysabri ® (natalizumab) |
Natalizumab |
D06886 |
1件: ITGA4 |
14件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection |
1件: 13 |
1367 |
Tysabri® |
Natalizumab |
D06886 |
1件: ITGA4 |
14件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection |
1件: 13 |
1368 |
Tysabri® (natalizumab) |
Natalizumab |
D06886 |
1件: ITGA4 |
14件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection |
1件: 13 |
1369 |
Ublituximab |
Ublituximab |
D11243 |
1件: MS4A1 |
1件: Hematopoietic cell lineage |
1件: 13 |
1370 |
Ucb l059 |
Levetiracetam |
D00709 |
1件: SV2A |
1件: ECM-receptor interaction |
1件: 13 |
1371 |
Ultra small particles of iron oxide (uspio) |
Iron |
- |
- |
- |
1件: 13 |
1372 |
Ultrasmall particles of iron oxide |
Iron |
- |
- |
- |
1件: 13 |
1373 |
Umbilical cord derived mesenchymal stem cells |
- |
- |
- |
- |
1件: 13 |
1374 |
Umbilical cord mesenchymal stem cells |
- |
- |
- |
- |
5件: 13, 46, 57, 97, 113 |
1375 |
Undifferentiated autologous mesenchymal stem cells |
- |
- |
- |
- |
1件: 13 |
1376 |
Untreated to atorvastatin treatment |
Atorvastatin |
D00258, D00887, D07474 |
1件: HMGCR |
4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
1件: 13 |
1377 |
Urbason 40 mg |
- |
- |
- |
- |
1件: 13 |
1378 |
Urbason 40 mg comprimidos |
- |
- |
- |
- |
1件: 13 |
1379 |
Urbason forte |
- |
- |
- |
- |
1件: 13 |
1380 |
Urbason solubile forte 1000mg |
- |
- |
- |
- |
1件: 13 |
1381 |
Urbason® solubile forte 1000 mg |
- |
- |
- |
- |
1件: 13 |
1382 |
Urine samples |
- |
- |
- |
- |
1件: 13 |
1383 |
Uvedose 100 000 ui |
- |
- |
- |
- |
1件: 13 |
1384 |
Uvedose 100 000 ui, solution buvable en ampoule |
- |
- |
- |
- |
1件: 13 |
1385 |
V08ca02 |
- |
- |
- |
- |
1件: 13 |
1386 |
V08ca09 |
- |
- |
- |
- |
1件: 13 |
1387 |
Vaginal estriol |
Estriol |
D00185, D01986 |
2件: ESR1, ESR2 |
9件: Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway |
1件: 13 |
1388 |
Vardenafil |
Vardenafil |
D02731, D03260, D08668 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
3件: 13, 86, 299 |
1389 |
Vardenafil (hidrocloride) |
Vardenafil |
D02731, D03260, D08668 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
1件: 13 |
1390 |
Vardenafilo |
Vardenafil |
D02731, D03260, D08668 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
1件: 13 |
1391 |
Vardenafilo hidrocloruro |
Vardenafil |
D02731, D03260, D08668 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
1件: 13 |
1392 |
Vatelizumab |
Vatelizumab |
- |
- |
- |
1件: 13 |
1393 |
Vay736 |
- |
- |
- |
- |
7件: 13, 35, 46, 49, 53, 85, 95 |
1394 |
Vb13s1 |
- |
- |
- |
- |
1件: 13 |
1395 |
Vb5s2 |
- |
- |
- |
- |
1件: 13 |
1396 |
Vb6s5 |
- |
- |
- |
- |
1件: 13 |
1397 |
Venlafaxin hexal |
- |
- |
- |
- |
1件: 13 |
1398 |
Venlafaxine |
Venlafaxine |
D00821, D08670 |
2件: SLC6A2, SLC6A4 |
2件: Serotonergic synapse, Synaptic vesicle cycle |
3件: 6, 13, 46 |
1399 |
Venlafaxine hydrochloride |
Venlafaxine |
D00821, D08670 |
2件: SLC6A2, SLC6A4 |
2件: Serotonergic synapse, Synaptic vesicle cycle |
2件: 13, 46 |
1400 |
Verum arm receiving gilenya® |
- |
- |
- |
- |
1件: 13 |
1401 |
Verum arm receiving vitamin d oil |
Vitamin d |
- |
- |
- |
1件: 13 |
1402 |
Vigantol |
- |
- |
- |
- |
2件: 13, 65 |
1403 |
Vigantol oel |
- |
- |
- |
- |
3件: 13, 96, 97 |
1404 |
Vigantol oil |
- |
- |
- |
- |
1件: 13 |
1405 |
Vigantol® öl 20.000 i.e./ml |
- |
- |
- |
- |
1件: 13 |
1406 |
Vitamin a |
Vitamin a |
D00069, D06543 |
2件: RARA, RARB |
8件: Acute myeloid leukemia, Estrogen signaling pathway, Gastric cancer, Non-small cell lung cancer, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Transcriptional misregulation in cancer |
3件: 13, 53, 90 |
1407 |
Vitamin d |
Vitamin d |
- |
- |
- |
18件: 13, 19, 41, 46, 49, 50, 68, 93, 95, 96, 98, 179, 222, 228, 235, 274, 298, 299 |
1408 |
Vitamin d3 |
Cholecalciferol |
D00188 |
1件: VDR |
4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
11件: 6, 13, 20, 46, 49, 53, 60, 65, 96, 97, 299 |
1409 |
Vitamin e |
Vitamin e |
D02331 |
- |
- |
11件: 2, 6, 13, 20, 46, 90, 96, 97, 206, 299, 317 |
1410 |
Vitamin e/selenium |
Vitamin e |
D02331 |
- |
- |
1件: 13 |
1411 |
Vitamin k |
Phylloquinone |
D00148 |
- |
- |
3件: 13, 46, 96 |
1412 |
Vitamina d3 kern pharma solución oleosa |
- |
- |
- |
- |
1件: 13 |
1413 |
Vsn16r |
- |
- |
- |
- |
1件: 13 |
1414 |
Vsn16r 100mg |
- |
- |
- |
- |
1件: 13 |
1415 |
Vx15/2503 |
Pepinemab |
D11469 |
1件: SEMA4D |
1件: Axon guidance |
2件: 8, 13 |
1416 |
Warfarin |
Warfarin |
D00564, D01280, D08682 |
2件: NQO1, VKORC1 |
5件: Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Metabolic pathways, Pathways in cancer, Ubiquinone and other terpenoid-quinone biosynthesis |
10件: 6, 8, 13, 19, 46, 49, 66, 85, 88, 96 |
1417 |
Water |
Water |
D00001 |
- |
- |
18件: 2, 5, 6, 13, 17, 19, 35, 46, 53, 57, 63, 65, 67, 84, 97, 226, 278, 299 |
1418 |
Way-130799 |
- |
- |
- |
- |
1件: 13 |
1419 |
Xbd173 |
- |
- |
- |
- |
1件: 13 |
1420 |
Xcel-mc-alpha |
- |
- |
- |
- |
1件: 13 |
1421 |
Xeomin |
Botulinum toxin type a |
D00783 |
1件: SNAP25 |
2件: Insulin secretion, Synaptic vesicle cycle |
7件: 5, 6, 7, 13, 15, 17, 113 |
1422 |
Zenapax |
Daclizumab |
D03639 |
1件: IL2RA |
11件: Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
1件: 13 |
1423 |
Zk 157046 |
- |
- |
- |
- |
1件: 13 |
1424 |
Zol446h |
- |
- |
- |
- |
1件: 13 |
1425 |
Zoledronic acid |
Zoledronic acid |
D01968, D06378, D06379, D08689 |
1件: FDPS |
4件: Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis |
9件: 6, 13, 46, 93, 95, 96, 274, 299, 333 |
1426 |
Zoledronic acid monohydrate |
Zoledronic acid |
D01968, D06378, D06379, D08689 |
1件: FDPS |
4件: Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis |
1件: 13 |